```
  *    The Help Desk staff at this number will handle all APS    *
  *    related questions.                                        *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
  *    >>>>>>>>>>>>> NEW SUNDAY HOURS !!! <<<<<<<<<<<<<           *
  *                                                              *
  *    The APS is available:                                     *
  *            6:30am - 9:00pm Monday through Friday             *
  *            7:30am - 5:00pm Saturday, Sunday, Holidays        *
  *                                                              *
  *      APS is unavailable Thanksgiving Day, Christmas Day,     *
  *      and New Year's Day.                                     *
  *                                                              *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
FILE 'USPAT' ENTERED AT 14:25:39 ON 14 MAY 1998

  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
  *            W E L C O M E   T O   T H E                      *
  *         U. S.   P A T E N T   T E X T   F I L E             *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

=> s cd4(P)(antibod?)(P)(autoimmun? or arthritis or sclerosis)

          2027 CD4
         28008 ANTIBOD?
          4066 AUTOIMMUN?
         10097 ARTHRITIS
          3197 SCLEROSIS
L1          75 CD4(P)(ANTIBOD?)(P)(AUTOIMMUN? OR ARTHRITIS OR SCLEROSIS)

=> s l1/clm

           192 CD4/CLM
          7759 ANTIBOD?/CLM
           385 AUTOIMMUN?/CLM
           882 ARTHRITIS/CLM
           296 SCLEROSIS/CLM
L2           3 (CD4/CLM(P)(ANTIBOD?/CLM)(P)(AUTOIMMUN?/CLM OR ARTHRITIS/CL
M O
               R SCLEROSIS/CLM))

=> d l2 1-3


1.  5,750,105, May 12, 1998, Recombinant antibodies for human therapy;
Roland A. Newman, et al., 424/133.1, 137.1, 138.1, 177.1; 530/387.3
[IMAGE AVAILABLE]

2.  5,741,488, Apr. 21, 1998, Treatment of rheumatoid arthritis with
anti-CD4 antibodies in conjunction with anti-TNF antibodies; Marc
Feldman, et al., 424/154.1, 130.1, 141.1, 143.1, 144.1, 145.1, 153.1,
158.1, 173.1 [IMAGE AVAILABLE]

3.  4,695,459, Sep. 22, 1987, Method of treating autoimmune diseases that
are mediated by Leu3/CD4 phenotype T cells; Lawrence Steinman, et al.,
424/154.1, 173.1, 810; 514/825, 863, 866, 885; 530/388.75, 868; 935/107
[IMAGE AVAILABLE]

=> d l2 1-3 kwic
```

US PAT NO: 5,750,105 [IMAGE AVAILABLE] L2: 1 of 3

CLAIMS:

CLMS(8)

8. The method of claim 1, wherein the treatment comprises treatment of a disease selected from the group consisting of rheumatoid **arthritis**, eczema, and immuno-modulated diseases, and the antigen bound by the **antibody** is **CD4**.

US PAT NO: 5,741,488 [IMAGE AVAILABLE] L2: 2 of 3

CLAIMS:

CLMS(1)

We claim:

1. A method of treating rheumatoid **arthritis** in a mammal comprising administering to said mammal a therapeutically effective amount of anti-**CD4 antibody** and anti-TNF **antibody**.

US PAT NO: 4,695,459 [IMAGE AVAILABLE] L2: 3 of 3

CLAIMS:

CLMS(1)

We claim:

1. A method of treating a patient for an **autoimmune** disease that is mediated by Leu3(**CD4**) phenotype T cells comprising parenterally administering a therapeutically effective amount of an anti-Leu3(**CD4**) **antibody** that binds to said T cells to the patient.

=> d l3 1-3 date

'L3' NOT FOUND

=> d l2 1-3 date

L2: 1 of 3

TITLE: Recombinant antibodies for human therapy
US PAT NO: 5,750,105 [IMAGE AVAILABLE] DATE ISSUED: May 12, 1998
APPL-NO: 08/476,349 DATE FILED: Jun. 7, 1995
REL-US-DATA: Division of Ser. No. 379,072, Dec. 5, 1995, which is a continuation of Ser. No. 912,292, Jul. 10, 1992, abandoned, which is a continuation-in-part of Ser. No. 856,281, Mar. 23, 1992, abandoned, which is a continuation-in-part of Ser. No. 735,064, Jul. 25, 1991, abandoned.

L2: 2 of 3

TITLE: Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies
US PAT NO: 5,741,488 [IMAGE AVAILABLE] DATE ISSUED: Apr. 21, 1998
APPL-NO: 08/403,785 DATE FILED: May 3, 1995
PCT-NO: PCT/GB93/02070 PCT-FILED: Oct. 6, 1993
371-DATE: May 3, 1995

		102(E)-DATE:	May 3, 1995
PCT-PUB-NO:	WO94/08619	PCT-PUB-DATE:	Apr. 28, 1994

L2: 3 of 3

TITLE: Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells

US PAT NO:	4,695,459 [IMAGE AVAILABLE]	DATE ISSUED:	Sep. 22, 1987
APPL-NO:	06/686,126	DATE FILED:	Dec. 26, 1984

=> d his

(FILE 'USPAT' ENTERED AT 14:25:39 ON 14 MAY 1998)
L1 75 S CD4(P)(ANTIBOD?)(P)(AUTOIMMUN? OR ARTHRITIS OR SCLEROSIS
)
L2 3 S L1/CLM

=> d l1 1-75

1. 5,750,332, May 12, 1998, Peptomers with enhanced immunogenicity; Frank A. Robey, et al., 435/5, 974; 514/2, 13 [IMAGE AVAILABLE]

2. 5,750,105, May 12, 1998, Recombinant antibodies for human therapy; Roland A. Newman, et al., 424/133.1, 137.1, 138.1, 177.1; 530/387.3 [IMAGE AVAILABLE]

3. 5,747,265, May 5, 1998, Method for measuring the amount of a cell-associated molecule; George H. Parsons, et al., 435/7.2, 7.24 [IMAGE AVAILABLE]

4. 5,747,036, May 5, 1998, Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease; Michael Brenner, et al., 424/144.1, 154.1, 173.1, 178.1 [IMAGE AVAILABLE]

5. 5,741,899, Apr. 21, 1998, Chimeric receptors comprising janus kinase for regulating cellular pro liferation; Daniel J. Capon, et al., 536/23.4; 435/69.7, 320.1, 325, 377; 530/350, 387.3 [IMAGE AVAILABLE]

6. 5,741,488, Apr. 21, 1998, Treatment of rheumatoid **arthritis** with anti-**CD4 antibodies** in conjunction with anti-TNF **antibodies**; Marc Feldman, et al., 424/154.1, 130.1, 141.1, 143.1, 144.1, 145.1, 153.1, 158.1, 173.1 [IMAGE AVAILABLE]

7. 5,736,138, Apr. 7, 1998, Monoclonal antibodies with specific binding against membrane proteins on human cells, and pharmaceutical compositions containing them; Klaus Pfizenmaier, et al., 424/143.1, 133.1, 144.1, 152.1, 154.1, 172.1, 173.1, 809; 435/70.21; 530/351, 387.1, 388.22, 388.73, 388.85, 388.9, 399, 866 [IMAGE AVAILABLE]

8. 5,734,023, Mar. 31, 1998, MHC class II .beta. chain/peptide complexes useful in ameliorating deleterious immune responses; Bishwajit Nag, et al., 530/403; 424/185.1, 193.1; 530/300, 395, 402, 868 [IMAGE AVAILABLE]

9. 5,728,680, Mar. 17, 1998, Methods for normalizing numbers of lymphocytes; Vyacheslav G. Morozov, et al., 514/19, 9, 11 [IMAGE AVAILABLE]

10. 5,728,533, Mar. 17, 1998, Human .beta..sub.2 integrin .alpha.subunit; W. Michael Gallatin, et al., 435/7.1, 7.8; 530/350, 380 [IMAGE AVAILABLE]

11. 5,723,503, Mar. 3, 1998, Biological treatment for rheumatoid arthritis; J. Bruce Smith, et al., 424/93.1, 93.71, 534 [IMAGE AVAILABLE]

12. 5,718,883, Feb. 17, 1998, Transgenic animal model for autoimmune diseases; David M. Harlan, et al., 424/9.2; 435/172.3; 514/2; 800/2, DIG.1 [IMAGE AVAILABLE]

13. 5,714,350, Feb. 3, 1998, Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region; Man Sung Co, et al., 435/69.6; 424/133.1; 435/70.21, 71.1, 172.1; 530/387.3; 935/49, 50 [IMAGE AVAILABLE]

14. 5,712,149, Jan. 27, 1998, Chimeric receptor molecules for delivery of co-stimulatory signals; Margo R. Roberts, 435/252.3, 69.7, 320.1; 530/350; 536/23.4 [IMAGE AVAILABLE]

15. 5,710,257, Jan. 20, 1998, Method of causing selective immunosuppression using HL-60-related lectins; Jeffrey J. Seilhamer, et al., 530/396; 435/172.3; 530/350 [IMAGE AVAILABLE]

16. 5,707,626, Jan. 13, 1998, Methods of treating HIV infection using antibodies to the U2 small nuclear ribonuclear protein; Angeline Douvas, et al., 424/160.1, 148.1, 152.1, 172.1 [IMAGE AVAILABLE]

17. 5,705,732, Jan. 6, 1998, Universal donor cells; Peter J. Sims, et al., 800/2; 435/172.3; 536/23.1; 800/DIG.1 [IMAGE AVAILABLE]

18. 5,696,237, Dec. 9, 1997, Recombinant antibody-toxin fusion protein; David FitzGerald, et al., 530/387.3, 388.22, 391.7 [IMAGE AVAILABLE]

19. 5,693,780, Dec. 2, 1997, Recombinant antibodies for human therapy; Roland A. Newman, et al., 536/23.53; 435/252.3, 320.1 [IMAGE AVAILABLE]

20. 5,693,760, Dec. 2, 1997, Method of causing selective immunosuppression using HL-60 related lectins; Jeffrey J. Seilhammer, et al., 530/396; 424/278.1; 435/172.3; 530/350, 827 [IMAGE AVAILABLE]

21. 5,693,617, Dec. 2, 1997, Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein; Ross L. Stein, et al., 514/18, 19; 530/331; 560/20, 27, 31, 32, 41, 47, 159 [IMAGE AVAILABLE]

22. 5,690,933, Nov. 25, 1997, Monoclonal antibodies for inducing tolerance; Stephen Paul Cobbold, et al., 424/144.1, 143.1, 153.1, 154.1, 173.1; 514/11 [IMAGE AVAILABLE]

23. 5,686,281, Nov. 11, 1997, Chimeric receptor molecules for delivery of co-stimulatory signals; Margo R. Roberts, 435/172.3, 7.1, 7.2, 69.7; 536/23.4 [IMAGE AVAILABLE]

24. 5,681,722, Oct. 28, 1997, Recombinant antibodies for human therapy; Roland A. Newman, et al., 435/69.7, 6, 91.2; 530/387.3; 536/23.53, 24.33 [IMAGE AVAILABLE]

25. 5,675,060, Oct. 7, 1997, Transgenic arthritic mice expressing a T-cell receptor transgene; Christophe O. Benoist, et al., 800/2; 424/9.2 [IMAGE AVAILABLE]

26. 5,674,692, Oct. 7, 1997, Methods for diabetes susceptibility assessment in asymptomatic patients; Steinunn Baekkeskov, et al., 435/7.21, 7.4; 436/506, 518 [IMAGE AVAILABLE]

27. 5,674,487, Oct. 7, 1997, Method for treating autoimmune diseases; J. Bruce Smith, et al., 424/93.71, 93.7 [IMAGE AVAILABLE]

28. 5,670,324, Sep. 23, 1997, Use of chimeric CD4-src protein tyrosine kinases in drug screening and detection of an immune response; Dan Littman, et al., 435/6, 15, 69.7 [IMAGE AVAILABLE]

29. 5,670,150, Sep. 23, 1997, Non-depleting CD4-specific monoclonal antibodies for the treatment of insulin-dependent diabetes mellitus (IDDM); Anne Cooke, et al., 424/154.1, 143.1, 145.1, 158.1; 530/388.24, 388.75 [IMAGE AVAILABLE]

30. 5,667,967, Sep. 16, 1997, T-cell receptor varible transcripts as disease related markers; Lawrence Steinman, et al., 435/6, 91.2; 935/77, 78 [IMAGE AVAILABLE]

31. 5,665,772, Sep. 9, 1997, O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants; Sylvain Cottens, et al., 514/514; 540/456 [IMAGE AVAILABLE]

32. 5,665,764, Sep. 9, 1997, Tricyclic inhibitors of matrix metalloproteinases; Donald Hupe, et al., 514/468; 549/460, 461 [IMAGE AVAILABLE]

33. 5,658,745, Aug. 19, 1997, Cell enumeration immunoassay; Richard Alfred Greene, et al., 435/7.24; 424/154.1, 534; 435/7.92, 7.95, 967, 974; 436/63, 172, 524, 531, 541, 546, 548, 811 [IMAGE AVAILABLE]

34. 5,658,570, Aug. 19, 1997, Recombinant antibodies for human therapy; Roland A. Newman, et al., 424/184.1; 435/69.6, 70.21, 172.2, 172.3; 530/388.22; 935/96 [IMAGE AVAILABLE]

35. 5,639,869, Jun. 17, 1997, Mycoplasma arthritidis T-cell mitogen; Barry C. Cole, et al., 536/23.7; 424/264.1; 530/326, 350, 825 [IMAGE AVAILABLE]

36. 5,635,599, Jun. 3, 1997, Fusion proteins comprising circularly permuted ligands; Ira H. Pastan, et al., 530/351; 435/69.1, 69.5, 69.52, 69.7, 172.3; 530/350 [IMAGE AVAILABLE]

37. 5,627,206, May 6, 1997, Tricyclic inhibitor of matrix metalloproteinases; Donald Hupe, et al., 514/468; 549/461 [IMAGE AVAILABLE]

38. 5,627,035, May 6, 1997, Peptides that block human immunodeficiency virus and methods of use thereof; Anders Vahlne, et al., 435/7.2; 424/188.1; 530/327, 328, 329, 330 [IMAGE AVAILABLE]

39. 5,626,843, May 6, 1997, Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor; Simon V. Skurkovich, et al., 424/140.1; 604/6 [IMAGE AVAILABLE]

40. 5,624,895, Apr. 29, 1997, Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration; Douglas Sobel, 514/8; 424/85.1, 85.2, 85.4, 85.5, 85.6, 85.7; 514/866 [IMAGE AVAILABLE]

41. 5,622,853, Apr. 22, 1997, T lymphocyte precursor; Leon W. M. M. Terstappen, et al., 435/372.3, 2, 7.2, 325 [IMAGE AVAILABLE]

42. 5,620,889, Apr. 15, 1997, Human anti-Fas IgG1 monoclonal antibodies; David H. Lynch, et al., 435/332; 424/144.1; 435/334, 343.2; 530/387.1, 388.2, 388.23, 388.24, 388.75 [IMAGE AVAILABLE]

43. 5,616,458, Apr. 1, 1997, Tripterygium wilfordii hook F extracts and components, and uses thereof; Peter E. Lipsky, et al., 435/4; 424/78.05, 195.1; 435/7.5, 7.9; 514/469, 821, 825, 886 [IMAGE AVAILABLE]

44. 5,614,192, Mar. 25, 1997, T cell receptor peptides as therapeutics for immune-related disease; Arthur A. Vandenbark, 424/185.1, 184.1, 193.1; 514/2, 12, 16; 530/300, 324, 328, 868 [IMAGE AVAILABLE]

45. 5,602,095, Feb. 11, 1997, Recombinant pseudomonas exotoxin with increased activity; Ira H. Pastan, et al., 514/12; 424/192.1, 193.1, 236.1; 435/69.1, 69.3, 69.7, 172.3, 252.3, 252.33, 320.1; 514/2; 530/350, 351, 403, 825; 930/200 [IMAGE AVAILABLE]

46. 5,583,153, Dec. 10, 1996, Use of taxol in the treatment of rheumatoid arthritis; Ernest Brahn, 514/449, 475 [IMAGE AVAILABLE]

47. 5,583,033, Dec. 10, 1996, T lymphocyte precursor; Leon W. M. M. Terstappen, et al., 435/7.21, 7.24, 378 [IMAGE AVAILABLE]

48. 5,580,772, Dec. 3, 1996, Association between a novel human intracisternal A-type retroviral particle-type II (HIAP-II) and idiopathic CD4+ T-lymphocytopenia (ICL); Robert F. Garry, Jr., 435/235.1; 424/207.1; 435/5, 239 [IMAGE AVAILABLE]

49. 5,580,562, Dec. 3, 1996, Preparations and uses thereof for immunosuppression; Peter E. Lipsky, et al., 424/195.1; 514/885, 908; 549/228, 297, 298 [IMAGE AVAILABLE]

50. 5,571,507, Nov. 5, 1996, Methods of treating diabetes; Vicki E. Rubin-Kelley, et al., 424/85.2; 514/866; 530/321, 351 [IMAGE AVAILABLE]

51. 5,556,754, Sep. 17, 1996, Methods for assessing the ability of a candidate drug to suppress MHC class I expression; Dinah S. Singer, et al., 435/6, 91.1; 436/63, 501; 536/24.31, 24.33; 935/34, 36, 77, 78 [IMAGE AVAILABLE]

52. 5,550,132, Aug. 27, 1996, Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines; Bradley J. Benson, et al., 514/269, 274; 544/311, 312, 313, 314 [IMAGE AVAILABLE]

53. 5,545,716, Aug. 13, 1996, Superantigen agonist and antagonist peptides; Howard M. Johnson, et al., 530/324, 325, 326 [IMAGE AVAILABLE]

54. 5,538,854, Jul. 23, 1996, Method for the determination of predisposition to autoimmune disease; Denise Faustman, 435/7.24, 6; 436/86, 506, 516 [IMAGE AVAILABLE]

55. 5,521,288, May 28, 1996, CD28IG fusion protein; Peter S. Linsley, et al., 530/387.3; 435/7.2, 7.92, 69.1, 69.7, 91.1, 252.3, 252.33, 320.1; 530/300, 350, 387.1, 395, 409, 866, 867, 868; 536/23.1, 23.4, 23.53 [IMAGE AVAILABLE]

56. 5,519,114, May 21, 1996, Retroviral superantigens, superantigen peptides, and methods of use; Howard M. Johnson, et al., 530/324; 424/188.1, 278.1; 435/5; 930/221 [IMAGE AVAILABLE]

57. 5,514,661, May 7, 1996, Immunological activity of rhamnolipids; Goran Piljac, et al., 514/25, 814, 861, 863, 864, 878, 883, 885, 886, 887, 889, 903, 908 [IMAGE AVAILABLE]

58. 5,504,000, Apr. 2, 1996, Chimeric protein tyrosine kinases; Dan Littman, et al., 435/194, 69.1, 69.7; 530/350; 536/22.1, 23.1, 23.2, 23.4, 23.5 [IMAGE AVAILABLE]

59. 5,500,340, Mar. 19, 1996, Inhibition of IL-2 production by Tripterygium wilfordii Hook F extract; Peter E. Lipsky, et al., 435/6; 436/63; 935/34, 77 [IMAGE AVAILABLE]

60. 5,468,481, Nov. 21, 1995, MHC class II-peptide conjugates useful in ameliorating autoimmunity; Somesh D. Sharma, et al., 424/185.1, 184.1, 193.1, 278.1; 514/2, 8; 530/395, 402, 403, 868 [IMAGE AVAILABLE]

61. 5,466,675, Nov. 14, 1995, Immunological activity of rhamnolipids; Goran Piljac, et al., 514/25, 814, 861, 863, 864, 878, 883, 885, 886, 887, 889, 903, 908 [IMAGE AVAILABLE]

62. 5,445,940, Aug. 29, 1995, Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease; Michael B. Brenner, et al., 435/7.24, 6; 436/501, 506, 512, 548 [IMAGE AVAILABLE]

63. 5,439,819, Aug. 8, 1995, Chimeric protein tyrosine kinases; Dan Littman, et al., 435/372.3, 69.1, 69.7, 194; 530/350; 536/22.1, 23.1, 23.2, 23.4, 23.5 [IMAGE AVAILABLE]

64. 5,397,702, Mar. 14, 1995, Assay for and treatment of autoimmune diseases; Michael D. Cahalan, et al., 435/69.1, 6, 172.3; 536/23.1, 23.5, 25.5 [IMAGE AVAILABLE]

65. 5,294,443, Mar. 15, 1994, Tripterygium wilford II hook f extracts and components thereof for immunosuppression; Peter E. Lipsky, et al., 424/195.1; 514/885 [IMAGE AVAILABLE]

66. 5,284,935, Feb. 8, 1994, MHC-mediated toxic conjugates useful in ameliorating autoimmunity; Brian R. Clark, et al., 424/185.1, 193.1, 810; 530/395, 403, 806, 807, 868 [IMAGE AVAILABLE]

67. 5,270,199, Dec. 14, 1993, Human mannose-binding protein; Raymond A. B. Ezekowitz, 435/372.1, 69.1, 172.3, 235.1, 252.3, 252.33, 254.11, 254.2, 320.1; 530/350; 536/23.4, 23.5; 935/18, 27, 32, 34, 38, 55, 62, 70, 72 [IMAGE AVAILABLE]

68. 5,260,422, Nov. 9, 1993, MHC conjugates useful in ameliorating autoimmunity; Brian R. Clark, et al., 424/185.1, 193.1, 810; 530/402, 403, 868 [IMAGE AVAILABLE]

69. 5,252,556, Oct. 12, 1993, Fragment capable of binding anti-CD43 autoantibodies; Blair Ardman, 424/185.1; 435/69.1, 69.3; 514/8; 530/350, 395 [IMAGE AVAILABLE]

70. 5,246,970, Sep. 21, 1993, Method of inhibiting nitric oxide formation; Joseph R. Williamson, et al., 514/632, 903 [IMAGE AVAILABLE]

71. 5,223,426, Jun. 29, 1993, Monoclonal antibodies reactive with defined regions of the T-cell antigen receptor; Robert V. Skibbens, et al., 435/331; 424/144.1, 154.1; 530/387.1, 387.9, 388.22, 388.75 [IMAGE AVAILABLE]

72. 5,194,425, Mar. 16, 1993, MHC-mediated toxic conjugates useful in ameliorating autoimmunity; Somesh D. Sharma, et al., 424/193.1, 185.1; 514/8, 903; 530/395, 402, 403 [IMAGE AVAILABLE]

73. 5,158,884, Oct. 27, 1992, Immunodominant acetylcholine receptor peptides useful for T-helper cell sensitization; Bianca M. Conti-Tronconi, et al., 435/331; 530/326 [IMAGE AVAILABLE]

74. 5,130,297, Jul. 14, 1992, Conjugates useful in ameliorating autoimmunity MHC-II-peptide; Somesh D. Sharma, et al., 514/8, 825, 903; 530/395, 403, 838 [IMAGE AVAILABLE]

75. 4,695,459, Sep. 22, 1987, Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells; Lawrence Steinman, et al., 424/154.1, 173.1, 810; 514/825, 863, 866, 885; 530/388.75, 868; 935/107 [IMAGE AVAILABLE]

```
ber

DIALOG INFORMATION SERVICES
PLEASE LOGON:
 ********
ENTER PASSWORD:
□p58093fe
 ********
Welcome to DIALOG

Dialog level 98.04.30D

Last logoff:  18may98 14:04:41
Logon file001 18may98 17:20:42
* * * As of March 23,1998, SRC1, INFO, and EIDDS will no longer be part
* * * of the Dialorder service. You may choose another supplier or go
* * * to http://uncweb.carl.org/ to find out about UnCover's complete
* * * document ordering service.
* * *
*** File 728 is not working. ***

File   1:ERIC  1966-1998/Mar
       (c) format only 1998 The Dialog Corporation

      Set  Items  Description
      ---  -----  -----------
? b 410

       18may98 17:20:47 User208760 Session D1032.1
            $0.03    0.001 Hrs File1
     $0.03  Estimated cost File1
     $0.03  Estimated cost this search
     $0.03  Estimated total session cost   0.001 Hrs.

File 410:Chronolog(R)  1981-1998/May
       (c) 1998 The Dialog Corporation plc

      Set  Items  Description
      ---  -----  -----------
? set hi ;set hi

HILIGHT set on as ''
HILIGHT set on as ''
? begin 55,72,154,399,351

       18may98 17:21:02 User208760 Session D1032.2
            $0.00    0.004 Hrs File410
     $0.00  Estimated cost File410
     $0.01  FTSNET
     $0.01  Estimated cost this search
     $0.04  Estimated total session cost   0.005 Hrs.

SYSTEM:OS  - DIALOG OneSearch
  File  55:BIOSIS PREVIEWS(R)  1985-1998/May W2
        (c) 1998 BIOSIS
  File  72:EMBASE  1985-1998/May W2
        (c) 1998 Elsevier Science B.V.
  File 154:MEDLINE(R)  1985-1998/Jul W2
        (c) format only 1998 Dialog Corporation
```

```
  File 399:CA SEARCH(R)  1967-1998/UD=12820
         (c) 1998 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
RANK charge added; see HELP RATES 399.
  File 351:DERWENT WPI  1963-1998/UD=9819;UP=9816;UM=9814
         (c)1998 Derwent Info Ltd
*File 351: Some images missing from UD=9816-9818 to be added as soon as
possible. Output formats changed for 1998. See HELP FORM 351 for info.

      Set  Items  Description
      ---  -----  -----------
? s (non(w)deplet? or nondeplet?) and (antibod? or immunoglobulin?)

Processing
         2777715  NON
          162261  DEPLET?
             270  NON(W)DEPLET?
             400  NONDEPLET?
         1034528  ANTIBOD?
          319454  IMMUNOGLOBULIN?
      S1     312  (NON(W)DEPLET? OR NONDEPLET?) AND (ANTIBOD? OR
                  IMMUNOGLOBULIN?)
? s s1 and cd4

             312  S1
          103565  CD4
      S2     224  S1 AND CD4
? s s2 and human?

Processing
             224  S2
         9670595  HUMAN?
      S3      67  S2 AND HUMAN?
? rd s3

>>>Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.
...examined 50 records  (50)
...completed examining records
      S4      45  RD S3 (unique items)
? t s4/3/all


 4/3/1     (Item 1 from file: 55)
DIALOG(R)File  55:BIOSIS PREVIEWS(R)
(c) 1998 BIOSIS. All rts. reserv.

14176107     BIOSIS Number: 01176107
  Treatment of recalcitrant plaque psoriasis with a humanized
non-depleting antibody to CD4
  Bachelez H; Flageul B; Dubertret L; Fraitag S; Grossman R; Brousse N;
Poisson D; Knowles R W; Wacholtz M C; Haverty T; Chatenoud L; Bach J-F
  Hopital Necker, 161 Rue de Sevres, Paris, France
  Journal of Autoimmunity 11 (1). 1998.  53-62.
  Full Journal Title:  Journal of Autoimmunity
  ISSN: 0896-8411
  Language: ENGLISH
  Print Number: Biological Abstracts Vol. 105 Iss. 009 Ref. 118819


 4/3/2     (Item 2 from file: 55)
DIALOG(R)File  55:BIOSIS PREVIEWS(R)
(c) 1998 BIOSIS. All rts. reserv.
```

14157891 BIOSIS Number: 01157891
Reduction of Th1 cell activity in patients with rheumatoid arthritis after treatment with a **non-depleting** monoclonal **antibody** to **CD4**
Schulze-Koops H; Davis L S; Haverty P; Wacholtz M C; Lipsky P E
Southwestern Med. Cent., Dallas, TX, USA
Arthritis & Rheumatism 40 (9 SUPPL.). 1997. S191.
Full Journal Title: 61st National Scientific Meeting of the American College of Rheumatology and the 32nd National Scientific Meeting of the Association of Rheumatology Health Professionals, Washington, DC, USA, November 8-12, 1997. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 050 Iss. 004 Ref. 065775

4/3/3 (Item 3 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

14157060 BIOSIS Number: 01157060
Effect of a **humanized non-depleting** anti-**CD4** monoclonal **antibody** (mAb) on synovial fluid (SF) in rheumatoid arthritis (RA)
Choy E H S; Connolly D J A; Rapson N; Kingsley G H; Johnston J M; Panayi G S
Rheumatol. Unit, Guy's and King's Coll. Hosp., London, UK
Arthritis & Rheumatism 40 (9 SUPPL.). 1997. S52.
Full Journal Title: 61st National Scientific Meeting of the American College of Rheumatology and the 32nd National Scientific Meeting of the Association of Rheumatology Health Professionals, Washington, DC, USA, November 8-12, 1997. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 050 Iss. 004 Ref. 064944

4/3/4 (Item 4 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

14126123 BIOSIS Number: 01126123
Nondepleting humanized anti-**CD4** monoclonal **antibody** in patients with refractory rheumatoid arthritis
Moreland L W; Haverty T P; Wacholtz M C; Knowles R W; Bucy R P; Heck L W Jr; Koopman W J
Div. Rheumatology, Univ. Ala., 1717 6th Ave. South, Room 068, Birmingham, AL 35294-7201, USA
Journal of Rheumatology 25 (2). 1998. 221-228.
Full Journal Title: Journal of Rheumatology
ISSN: 0315-162X
Language: ENGLISH
Print Number: Biological Abstracts Vol. 105 Iss. 006 Ref. 084997

4/3/5 (Item 5 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

14107479 BIOSIS Number: 01107479
Therapeutically effective **humanised non-depleting** anti-**CD4** monoclonal **antibody** (mAb) 4162W94 has no effect on monocytoid cell lines

Newman I; Connolly D A; Choy E H S; Rapson N T; Panayi G S
Rheumatol. Unit, UMDS and King's Coll. Hosp., London SE1 9RT, UK
Immunology 92 (SUPPL. 1). 1997. 117.
Full Journal Title: 5th Annual Congress of the British Society for Immunology, Brighton, England, UK, December 2-5, 1997. Immunology
ISSN: 0019-2805
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 050 Iss. 003 Ref. 041391

4/3/6 (Item 6 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

14010282 BIOSIS Number: 01010282
Humanized anti-**CD4** monoclonal **antibody** therapy of autoimmune and inflammatory disease
Isaacs J D; Burrows N; Wing M; Keogan M T; Rebello P R U B; Watts R A; Pye R J; Norris P; Hazelman B L; Hale G; Waldmann H
Molecular Med. Unit, Clin. Sci. Build., St. James's Univ. Hosp., Leeds LS9 7TF, UK
Clinical and Experimental Immunology 110 (2). 1997. 158-166.
Full Journal Title: Clinical and Experimental Immunology
ISSN: 0009-9104
Language: ENGLISH
Print Number: Biological Abstracts Vol. 105 Iss. 001 Ref. 010282

4/3/7 (Item 7 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13658881 BIOSIS Number: 99658881
A **humanized** form of a **CD4**-specific monoclonal **antibody** exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties
Reimann K A; Lin W; Bixler S; Browning B; Ehrenfels B N; Lucci J; Miatkowski K; Olson D; Parish T H; Rosa M D; Oleson F B; Hsu Y M; Padlan E A; Letvin N L; Burkly L C
Division Viral Pathogenesis, Beth Israel Deaconess Med. Cent., RE-113, 330 Brookline Ave., Boston, MA 02215, USA
AIDS Research and Human Retroviruses 13 (11). 1997. 933-943.
Full Journal Title: AIDS Research and Human Retroviruses
ISSN: 0889-2229
Language: ENGLISH
Print Number: Biological Abstracts Vol. 104 Iss. 005 Ref. 067280

4/3/8 (Item 8 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13627855 BIOSIS Number: 99627855
The immunological and pharmacodynamic effects of a **humanised** **non-depleting** anti-**CD4** monoclonal **antibody** (mAb) in rheumatoid arthritis (RA)
Choy E H S; Connolly D J A; Regan T; Manna V K; Rapson N; Kingsley G H; Panayi G S; Johnston J M
Glaxo Wellcome, Beckenham, London, UK
British Journal of Rheumatology 36 (SUPPL. 1). 1997. 185.
Full Journal Title: XIVth Annual General Meeting of the British Society of Rheumatology, Harrogate, England, UK, April 23-25, 1997. British Journal of Rheumatology
ISSN: 0263-7103

Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 049 Iss. 008 Ref. 134420

4/3/9 (Item 9 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13627731 BIOSIS Number: 99627731
The clinical effect of a by **humanised non-depleting** anti-**CD4** monoclonal **antibody** (mAb) in rheumatoid arthritis (RA)
Panayi G S; Chov E H S; Connolly D J A; Manna V K; Regan T; Rapson N; Kingsley G H; Johnston J M
Rheumatology Unit, Guy's Hosp., UMDS, London, UK
British Journal of Rheumatology 36 (SUPPL. 1). 1997. 122.
Full Journal Title: XIVth Annual General Meeting of the British Society of Rheumatology, Harrogate, England, UK, April 23-25, 1997. British Journal of Rheumatology
ISSN: 0263-7103
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 049 Iss. 008 Ref. 134296

4/3/10 (Item 10 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13402315 BIOSIS Number: 99402315
T cell hypothesis in rheumatoid arthritis (RA) tested by **humanised non-depleting** anti-**CD4** monoclonal **antibody** (mAb) treatment I: Suppression of disease activity and acute phase response
Panayi G S; Choy E H S; Connolly D J A; Manna V K; Regan T; Rapson N; Kingsley G H; Johnston J M
Rheumatology Unit, Guy's Hosp., UMDS, London, UK
Immunology 89 (SUPPL. 1). 1996. 92.
Full Journal Title: Joint Congress of the British Society for Immunology and the Biochemical Society, Harrogate, England, UK, December 10-13, 1996. Immunology
ISSN: 0019-2805
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 049 Iss. 003 Ref. 048954

4/3/11 (Item 11 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13402314 BIOSIS Number: 99402314
T cell hypothesis in rheumatoid arthritis (RA) tested by **humanised non-depleting** anti-**CD4** monoclonal **antibody** (mAb) treatment II: Clinical activity is related to pharmacodynamic effects
Choy E H S; Connolly D J A; Regan T; Manna V K; Rapson N; Kingsley G H; Panayi G S; Johnston J M
Rheumatology Unit, Guy's Hosp., UMDS, London, UK
Immunology 89 (SUPPL. 1). 1996. 92.
Full Journal Title: Joint Congress of the British Society for Immunology and the Biochemical Society, Harrogate, England, UK, December 10-13, 1996. Immunology
ISSN: 0019-2805
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 049 Iss. 003 Ref. 048953

4/3/12 (Item 12 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13224264 BIOSIS Number: 99224264
T cell hypothesis in rheumatoid arthritis (RA) tested by **humanized non-depleting** anti-**CD4** monoclonal **antibody** (mAb)
treatment III: Immunological effects
Connolly D J A; Choy E H S; Rapson N; Regan T; Kingsley G H; Johnston J M ; Panayi G S
Rheumatol. Unit, Guy's Hosp., UMDS, London, UK
Arthritis & Rheumatism 39 (9 SUPPL.). 1996. S245.
Full Journal Title: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals, Orlando, Florida, USA, October 18-22, 1996. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 011 Ref. 203385

4/3/13 (Item 13 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13224263 BIOSIS Number: 99224263
T cell hypothesis in rheumatoid arthritis (RA) tested by **humanized non-depleting** anti-**CD4** monoclonal **antibody** (mAb)
treatment II: Clinical activity is related to pharmacodynamic effects
Choy E H S; Connolly D J A; Regan T; Manna V K; Rapson N; Kingsley G H; Panayi G S; Johnston J M
Rheumatol. Unit, Guy's Hosp., UMDS, London, UK
Arthritis & Rheumatism 39 (9 SUPPL.). 1996. S244.
Full Journal Title: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals, Orlando, Florida, USA, October 18-22, 1996. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 011 Ref. 203384

4/3/14 (Item 14 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13224262 BIOSIS Number: 99224262
T cell hypothesis in rheumatoid arthritis (RA) tested by **humanized non-depleting** anti-**CD4** monoclonal **antibody** (mAb)
treatment I: Suppression of disease activity and acute phase response
Panayi G S; Choy E H S; Connolly D J A; Regan T; Manna V K; Rapson N; Kingsley G H; Johnston J M
Rheumatol. Unit, Guy's Hosp., UMDS, London, UK
Arthritis & Rheumatism 39 (9 SUPPL.). 1996. S244.
Full Journal Title: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals, Orlando, Florida, USA, October 18-22, 1996. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER

Print Number: Biological Abstracts/RRM Vol. 048 Iss. 011 Ref. 203383

4/3/15 (Item 15 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13223537 BIOSIS Number: 99223537
Results of a placebo-controlled multicenter trial using a primatized **non-depleting**, anti-**CD4** monoclonal **antibody** in the treatment of rheumatoid arthritis
Levy R; Weisman M; Wisenhutter C; Yocum D; Schnitzer T; Goldman A; Schiff M; Leiden B F; Solinger A; MacDonald B; Lipani J
Olympia, WA 98502, USA
Arthritis & Rheumatism 39 (9 SUPPL.). 1996. S122.
Full Journal Title: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals, Orlando, Florida, USA, October 18-22, 1996. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 011 Ref. 202658

4/3/16 (Item 16 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

13031632 BIOSIS Number: 99031632
Immunological markers of response in a multi-dose protocol 7002 using an immunomodulating, **non-depleting** Primatized anti-**CD4** monoclonal **antibody** in rheumatoid arthritis (RA)
Solinger A; Paxton H; Wey K; Yocum D
IDEC Pharmaceuticals, San Diego, CA 92121, USA
FASEB Journal 10 (6). 1996. A1314.
Full Journal Title: Joint Meeting of the American Society for Biochemistry and Molecular Biology, the American Society for Investigative Pathology and the American Association of Immunologists, New Orleans, Louisiana, USA, June 2-6, 1996. FASEB Journal
ISSN: 0892-6638
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 007 Ref. 125368

4/3/17 (Item 17 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

12165809 BIOSIS Number: 98765809
Immunological markers of response in a multi-dose protocol 7002 using an immunomodulating, **non-depleting** primatized-TM anti-**CD4** monoclonal **antibody** in rheumatoid arthritis (RA)
Solinger A; Paxton H; Wey K; Yocum D
IDEC Pharmaceuticals, San Diego, CA 92121, USA
FASEB Journal 10 (3). 1996. A442.
Full Journal Title: Experimental Biology 96, Part II, Washington, D.C., USA, April 14-17, 1996. FASEB Journal
ISSN: 0892-6638
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 005 Ref. 082598

4/3/18 (Item 18 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11935571 BIOSIS Number: 98535571
Modulation of mitogen and recall antigen proliferation by a **non-depleting**, anti-**CD4** monoclonal **antibody**: Results of a multi-dose study
Yocum D E; Mararescu M; Soundararaian D; Nordensson K; Solinger A M; Lipani J
Univ. Ariz., Tucson, AZ 85724, USA
Arthritis & Rheumatism 38 (9 SUPPL.). 1995. S280.
Full Journal Title: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals, San Francisco, California, USA, October 21-26, 1995. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 047 Iss. 012 Ref. 205446

4/3/19 (Item 19 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11935007 BIOSIS Number: 98535007
Treating rheumatoid arthritis with a **non-depleting** anti-**CD4** monoclonal **antibody** (MAb)
Moreland L W; Bucy R P; Knowles R W; Wacholtz M C; Haverty T P; Koopman W J
Univ. Alabama at Birmingham, Birmingham, AL, USA
Arthritis & Rheumatism 38 (9 SUPPL.). 1995. S186.
Full Journal Title: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals, San Francisco, California, USA, October 21-26, 1995. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 047 Iss. 012 Ref. 204882

4/3/20 (Item 20 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11935003 BIOSIS Number: 98535003
Results of a multi-dose protocol 7002 using an immunomodulating, **non-depleting** PRIMATIZED anti-**cD4** monoclonal **antibody** in rheumatoid arthritis (RA)
Kaine J; Solinger A; Yocum D; Lipani J; Klas P; Tesser J; Wiesenhutter C; O'Sullivan F; Shuman S; Rigby W
Sarasota Arthritis Center, Sarasota, FL 34239, USA
Arthritis & Rheumatism 38 (9 SUPPL.). 1995. S185.
Full Journal Title: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals, San Francisco, California, USA, October 21-26, 1995. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 047 Iss. 012 Ref. 204878

4/3/21 (Item 21 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11922318 BIOSIS Number: 98522318
Therapeutic monoclonal **antibodies**
Choy E H S; Panayi G S; Kingsley G H
Rheumatol. Unit, Div. Medicine, UMDS, 4th Floor, Hunt's House, Guy's Hospital, St. Thomas Street, London SE1 9RT, UK
British Journal of Rheumatology 34 (8). 1995. 707-715.
Full Journal Title: British Journal of Rheumatology
ISSN: 0263-7103
Language: ENGLISH
Print Number: Biological Abstracts Vol. 100 Iss. 011 Ref. 173175

4/3/22 (Item 22 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11760328 BIOSIS Number: 98360328
Activation of **CD4**+ T cells in the presence of a **nondepleting** monoclonal **antibody** to **CD4** induces a Th2-Type response in vitro
Stumbles P; Mason D
MRC Cellular Immunol. Unit, Sir William Dunn Sch. Pathol., University Oxford, South Parks Rd., Oxford OX1 3RE, UK
Journal of Experimental Medicine 182 (1). 1995. 5-13.
Full Journal Title: Journal of Experimental Medicine
ISSN: 0022-1007
Language: ENGLISH
Print Number: Biological Abstracts Vol. 100 Iss. 004 Ref. 052166

4/3/23 (Item 23 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11345669 BIOSIS Number: 97545669
Immunological approach to inhibit formation of anti-**antibodies** to allo- and xenogeneic anti-T cell **immunoglobulin**
Mysliwietz J; Thierfelder S; Mocikat R; Kremmer E
GSF, Inst. Immunol., Marchioninistr. 25, D-81377 Muenchen, GER
European Journal of Immunology 24 (10). 1994. 2323-2328.
Full Journal Title: European Journal of Immunology
ISSN: 0014-2980
Language: ENGLISH
Print Number: Biological Abstracts Vol. 098 Iss. 012 Ref. 163292

4/3/24 (Item 24 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

10805769 BIOSIS Number: 97005769
T-cell recognition of a cross-reactive antigen(s) in erythrocytic stages of Plasmodium falciparum and Plasmodium yoelii: Inhibition of parasitemia by this antigen(s)
Lucas B; Engels A; Camus D; Haque A
Centre Immunol., Biol. Parasitaire, Inst. Pasteur, 59019 Lille, FRA
Infection and Immunity 61 (11). 1993. 4863-4869.
Full Journal Title: Infection and Immunity
ISSN: 0019-9567
Language: ENGLISH
Print Number: Biological Abstracts Vol. 097 Iss. 001 Ref. 005267

4/3/25 (Item 25 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

8095291 BIOSIS Number: 91016291
RESISTANCE TO INFECTION BY HIV-1 OF PERIPHERAL BLOOD MONONUCLEAR CELLS FROM HIV-1-INFECTED PATIENTS IS PROBABLY MEDIATED BY NEUTRALIZING **ANTIBODIES**
TREMBLAY M; NUMAZAKI K; LI X; GORNITSKY M; HISCOTT J; WAINBERG M A
MCGILL AIDS CENTRE JEWISH GENERAL HOSP., 3755 COTE STE-CATHERINE ROAD, MONTREAL, QUEBEC H3T 1E2, CAN.
J IMMUNOL 145 (9). 1990. 2896-2901. CODEN: JOIMA
Full Journal Title: Journal of Immunology
Language: ENGLISH

4/3/26 (Item 1 from file: 72)
DIALOG(R)File 72:EMBASE

10623307 EMBASE No: 98050169
Clinical pharmacology and therapeutic potential of monoclonal **antibody** treatment in rheumatoid arthritis
Choy E.H.S.
Dr. E.H.S. Choy, Rheumatology Unit, Thomas Guy House, Guy's Hospital, St Thomas Street, London SE1 9RT United Kingdom
Drugs and Aging (New Zealand) , 1998, 12/2 (139-148)
CODEN: DRAGE ISSN: 1170-229X
DOCUMENT TYPE: Journal Review
LANGUAGES: ENGLISH SUMMARY LANGUAGES: ENGLISH
NUMBER OF REFERENCES: 51

4/3/27 (Item 2 from file: 72)
DIALOG(R)File 72:EMBASE

9787616 EMBASE No: 95351540
T-cell regulation
Choy E.H.S.; Kingsley G.H.; Panayi G.S.
UMDS, Rheumatology Unit, Guy's Hospital, St Thomas Street, London SE1 9RT United Kingdom
Bailliere's Clinical Rheumatology (United Kingdom) , 1995, 9/4 (653-671)
CODEN: BCRHE ISSN: 0950-3579
LANGUAGES: English SUMMARY LANGUAGES: English

4/3/28 (Item 3 from file: 72)
DIALOG(R)File 72:EMBASE

9532547 EMBASE No: 95106020
Anti-**CD4** monoclonal **antibody** immune intervention in patients with newly diagnosed Type I (insulin-dependent) diabetes mellitus
Hehmke B.; Kuttler B.; Laube F.; Gens E.; Michaelis D.; Hahn H.-J.; Schulze-Koops H.; Emmrich F.
Institute Diabetes 'Gerhardt Katsch', Dept Experimental Clin Endocrinology, D-17495 Karlsburg Germany
Diabetes, Nutrition and Metabolism - Clinical and Experimental (Italy) , 1994, 7/5 (273-280)
CODEN: DNMEE ISSN: 0394-3402
LANGUAGES: English SUMMARY LANGUAGES: English

4/3/29 (Item 4 from file: 72)
DIALOG(R)File 72:EMBASE

8675097 EMBASE No: 92355607
Anti-**CD4** monoclonal **antibodies** in therapy: Creation of nonclassical tolerance in the adult
Shizuru J.A.; Alters S.E.; Fathman C.G.
Stanford Univ. School of Medicine, Div. of Rheumatology and Immunology, Stanford, CA 94305 USA
IMMUNOL. REV. (Denmark) , 1992, -/129 (105-130)
CODEN: IMRED ISSN: 0105-2896 ADONIS ORDER NUMBER: 010528969200046X
LANGUAGES: English SUMMARY LANGUAGES: English

4/3/30 (Item 5 from file: 72)
DIALOG(R)File 72:EMBASE

8398766 EMBASE No: 92074758
Comparison of GK1.5 and chimeric rat/mouse GK1.5 anti-**CD4** **antibodies** for prolongation of skin allograft survival and suppression of alloantibody production in mice
Rashid A.; Auchincloss H. Jr.; Sharon J.
Boston University School of Medicine, 80 East Concord St., Boston, MA 02118 USA
J. IMMUNOL. (USA) , 1992, 148/5 (1382-1388)
CODEN: JOIMA ISSN: 0022-1767
LANGUAGES: English SUMMARY LANGUAGES: English

4/3/31 (Item 6 from file: 72)
DIALOG(R)File 72:EMBASE

8183556 EMBASE No: 91209639
Monoclonal **antibody** therapy for the induction of transplantation tolerance
Cobbold S.P.
Division of Immunology, Cambridge University Department of Pathology, Tennis Court Road, Cambridge CB1 2QP United Kingdom
IMMUNOL. LETT. (Netherlands) , 1991, 29/1-2 (117-122)
CODEN: IMLED ISSN: 0165-2478 ADONIS ORDER NUMBER: 016524789100175N
LANGUAGES: English

4/3/32 (Item 7 from file: 72)
DIALOG(R)File 72:EMBASE

8013038 EMBASE No: 91038466
Induction of tolerance in peripheral T cells with monoclonal **antibodies**
Qin S.; Wise M.; Cobbold S.P.; Leong L.; Kong Y.-C.M.; Parnes J.R.; Waldmann H.
Division of Immunology, Department of Pathology, Cambridge University, Cambridge CB2 2QQ United Kingdom
EUR. J. IMMUNOL. (Germany, Federal Republic of) , 1990, 20/12 (2737-2745)
CODEN: EJIMA ISSN: 0014-2980
LANGUAGES: English

4/3/33 (Item 1 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

09479687 98184497
Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes.
Parr MB; Parr EL
School of Medicine, Southern Illinois University, Carbondale 62901, USA. mparr@som.siu.edu
J Virol (UNITED STATES) Apr 1998, 72 (4) p2677-85, ISSN 0022-538X Journal Code: KCV
Contract/Grant No.: HD-17337, HD, NICHD
Languages: ENGLISH
Document type: JOURNAL ARTICLE

4/3/34 (Item 2 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08916757 97172248
Induction of donor specific transplantation tolerance to cardiac allografts following treatment with **nondepleting** (RIB 5/2) or depleting (OX-38) anti-**CD4** mAb plus intrathymic or intravenous donor alloantigen.
Arima T; Lehmann M; Flye MW
Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Transplantation (UNITED STATES) Jan 27 1997, 63 (2) p284-92, ISSN 0041-1337 Journal Code: WEJ
Contract/Grant No.: 5PO1 AI35121, AI, NIAID
Languages: ENGLISH
Document type: JOURNAL ARTICLE

4/3/35 (Item 3 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08909043 97111516
Nondepleting anti-**CD4** **antibody** treatment prolongs lung-directed E1-deleted adenovirus-mediated gene expression in rats.
Lei D; Lehmann M; Shellito JE; Nelson S; Siegling A; Volk HD; Kolls JK
LSU Section of Pulmonary/Critical Care MEB, New Orleans 70112, USA.
Hum Gene Ther (UNITED STATES) Dec 1 1996, 7 (18) p2273-9, ISSN 1043-0342 Journal Code: A12
Contract/Grant No.: R29-AA10384, AA, NIAAA; HL-29246, HL, NHLBI
Languages: ENGLISH
Document type: JOURNAL ARTICLE

4/3/36 (Item 4 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08548769 96161423
Innovative treatment approaches for rheumatoid arthritis. T-cell regulation.
Choy EH; Kingsley GH; Panayi GS
UMDS, Rheumatology Unit, Guy's Hospital, London, UK.
Baillieres Clin Rheumatol (ENGLAND) Nov 1995, 9 (4) p653-71, ISSN 0950-3579 Journal Code: CRY
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

4/3/37 (Item 5 from file: 154)

DIALOG(R)File 154:MEDLINE(R)
(c) format only 1998 Dialog Corporation. All rts. reserv.

08010998 94321135
Sparing of the ipsilateral retina after anterior chamber inoculation of HSV-1: requirement for either **CD4**+ or CD8+ T cells.
Azumi A; Atherton SS
Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio 78284-7762.
Invest Ophthalmol Vis Sci (UNITED STATES) Jul 1994, 35 (8) p3251-9, ISSN 0146-0404 Journal Code: GWI
Contract/Grant No.: EY06012, EY, NEI
Languages: ENGLISH
Document type: JOURNAL ARTICLE

4/3/38 (Item 6 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1998 Dialog Corporation. All rts. reserv.

08005292 94131763
Modulation of murine herpes simplex virus type 1 retinitis in the uninoculated eye by **CD4**+ T lymphocytes.
Azumi A; Cousins SW; Kanter MY; Atherton SS
Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio 78284-7762.
Invest Ophthalmol Vis Sci (UNITED STATES) Jan 1994, 35 (1) p54-63, ISSN 0146-0404 Journal Code: GWI
Contract/Grant No.: EY06012, EY, NEI
Languages: ENGLISH
Document type: JOURNAL ARTICLE

4/3/39 (Item 7 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1998 Dialog Corporation. All rts. reserv.

07351119 93153366
Down regulation of stem cell colony formation by purified CD8 lymphocytes and CD8 conditioned medium: potential importance for bone marrow transplantation in leukemia.
Gazitt Y; He YJ
Department of Pediatric Hematology-Oncology, University of Florida, Gainesville.
Leuk Lymphoma (SWITZERLAND) Sep 1992, 8 (1-2) p117-27, ISSN 1042-8194 Journal Code: BNQ
Languages: ENGLISH
Document type: JOURNAL ARTICLE

4/3/40 (Item 8 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1998 Dialog Corporation. All rts. reserv.

07342782 92368404
The forces driving autoimmune disease.
Roitt IM; Hutchings PR; Dawe KI; Sumar N; Bodman KB; Cooke A
Dept. of Immunology, University College & Middlesex School of Medicine, London, UK.
J Autoimmun (ENGLAND) Apr 1992, 5 Suppl A p11-26, ISSN 0896-8411 Journal Code: ADL
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

4/3/41 (Item 9 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

06603039 91370929
Reprogramming the immune system for tolerance with monoclonal **antibodies**.
Cobbold SP; Qin SX; Waldmann H
Department of Pathology, Cambridge University, UK.
Semin Immunol (UNITED STATES) Nov 1990, 2 (6) p377-87, ISSN 1044-5323
Journal Code: A61
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

4/3/42 (Item 10 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

05517371 89001400
CD4+ T cells appear capable of initiating graft-versus-host disease across non-major histocompatibility complex (MHC) barriers in man.
Atkinson K; Cooley M; Farrelly H; O'Flaherty E; Ashby M; Biggs J
Department of Haematology, St Vincent's Hospital, Sydney, Australia.
Bone Marrow Transplant (ENGLAND) Jun 1987, 2 (1) p79-84, ISSN 0268-3369 Journal Code: BON
Languages: ENGLISH
Document type: JOURNAL ARTICLE

4/3/43 (Item 1 from file: 351)
DIALOG(R)File 351:DERWENT WPI

011033929
WPI Acc No: 97-011853/199701
XRAM Acc No: C97-003237
Amt. of **non-depleting** anti-**CD4 antibody** effective to induce immunological tolerance - useful to inhibit allo-graft rejection in primate subject, specifically bone marrow allo-graft
Patent Assignee: JOHNSON & JOHNSON CORP (JOHJ)
Inventor: CAVENDER D E; KNOWLES R W; THOMAS J M
Number of Countries: 069 Number of Patents: 002
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
WO 9636359	A1	19961121	WO 96US6912	A	19960516	A61K-039/395	199701 B
AU 9657479	A	19961129	AU 9657479	A	19960516	A61K-039/395	199712

Priority Applications (No Type Date): US 95443739 A 19950518
Filing Details:

Patent	Kind	Filing Notes	Application	Patent
WO 9636359	A1			
		Designated States (National): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN		
		Designated States (Regional): AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG		
AU 9657479	A	Based on	WO 9636359	

Language, Pages: WO 9636359 (E, 17)

4/3/44 (Item 2 from file: 351)
DIALOG(R)File 351:DERWENT WPI

009140953
WPI Acc No: 92-268391/199232
XRAM Acc No: C92-119699
Use of single **non-depleting CD4** monoclonal **antibody** - for treatment of insulin-dependent diabetes mellitus (IDDM), arrests loss of insulin producing cells
Patent Assignee: UNIV COLLEGE LONDON (UNLO); GLAXO WELLCOME PLC (GLAX)
Inventor: COOKE A; WALDMANN H
Number of Countries: 035 Number of Patents: 009
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
WO 9211869	A1	19920723	WO 92GB74	A	19920114	A61K-039/395	199232 B
AU 9211647	A	19920817	AU 9211647	A	19920114	A61K-039/395	199245
			WO 92GB74	A	19920114		
EP 567490	A1	19931103	EP 92902288	A	19920114	A61K-039/395	199344
			WO 92GB74	A	19920114		
JP 6504283	W	19940519	JP 92502777	A	19920114	A61K-039/395	199424
			WO 92GB74	A	19920114		
AU 668081	B	19960426	AU 9211647	A	19920114	A61K-039/395	199624
EP 567490	B1	19970813	EP 92902288	A	19920114	A61K-039/395	199737
			WO 92GB74	A	19920114		
DE 69221605	E	19970918	DE 621605	A	19920114	A61K-039/395	199743
			EP 92902288	A	19920114		
			WO 92GB74	A	19920114		
US 5670150	A	19970923	US 9390203	A	19931201	A61K-039/395	199744
			US 95436843	A	19950508		
ES 2106169	T3	19971101	EP 92902288	A	19920114	A61K-039/395	199750

Priority Applications (No Type Date): GB 91741 A 19910114
Filing Details:

Patent	Kind	Filing Notes	Application	Patent
WO 9211869	A1			
Designated States (National): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MW NL NO PL RO RU SD SE US				
Designated States (Regional): AT BE CH DE DK ES FR GB GR IT LU MC NL OA SE				
AU 9211647	A	Based on		WO 9211869
EP 567490	A1	Based on		WO 9211869
Designated States (Regional): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE				
JP 6504283	W	Based on		WO 9211869
AU 668081	B	Previous Publ.		AU 9211647
		Based on		WO 9211869
EP 567490	B1	Based on		WO 9211869
Designated States (Regional): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE				
DE 69221605	E	Based on		EP 567490
		Based on		WO 9211869
US 5670150	A	Cont of	US 9390203	
ES 2106169	T3	Based on		EP 567490

Language, Pages: WO 9211869 (E, 19); EP 567490 (E); JP 6504283 (5); EP 567490 (E, 6); US 5670150 (5)

4/3/45 (Item 3 from file: 351)
DIALOG(R)File 351:DERWENT WPI

008503137
WPI Acc No: 91-007221/199101
XRAM Acc No: C91-003203
Non-depleting CD4 and CD8 monoclonal **antibodies** - for inducting tolerance to foreign antigens in transplant rejection, auto-immune disease, etc
Patent Assignee: COBBOLD S P (COBB-I); WALDMANN H (WALD-I); WELLCOME FOUND

LTD (WELL); GLAXO WELLCOME INC (GLAX)
Inventor: COBBOLD S P; WALDMANN H
Number of Countries: 025 Number of Patents: 015
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
WO 9015152	A	19901213					199101 B
PT 94214	A	19910208					199109
AU 9057258	A	19910107					199115
EP 474691	A	19920318	EP 90908270	A	19900531		199212
ZA 9004174	A	19920226	ZA 904174	A	19900530		199213
DD 296843	A5	19911219	DD 341218	A	19900531	A61K-039/395	199221
JP 4505919	W	19921015	JP 90508030	A	19900531	A61K-039/395	199248
			WO 90GB840	A	19900531		
HU 61341	T	19921230	HU 905134	A	19900531	C12P-021/08	199306
			WO 90GB840	A	19900531		
AU 657255	B	19950309	AU 9057258	A	19900531	C12P-021/08	199520
EP 474691	B1	19961113	EP 90908270	A	19900531	C12P-021/08	199650
			WO 90GB840	A	19900531		
DE 69029134	E	19961219	DE 629134	A	19900531	C12P-021/08	199705
			EP 90908270	A	19900531		
			WO 90GB840	A	19900531		
ES 2096588	T3	19970316	EP 90908270	A	19900531	C12P-021/08	199718
NZ 233889	A	19970624	NZ 233889	A	19900531	A61K-039/395	199732
BR 1100287	A3	19970916	BR 971100287	A	19970415	C12P-021/08	199744
US 5690933	A	19971125	US 91768868	A	19910727	A61K-039/395	199802
			US 9347344	A	19930329		
			US 94181170	A	19940113		
			US 94289532	A	19940812		

Priority Applications (No Type Date): GB 8912497 A 19890531
Filing Details:

Patent	Kind	Filing Notes	Application	Patent
WO 9015152	A			
		Designated States (National): AU CA FI HU JP KR US		
		Designated States (Regional): AT BE CH DE DK ES FR GB IT LU NL SE		
EP 474691	A			
		Designated States (Regional): AT BE CH DE DK ES FR GB IT LI LU NL SE		
JP 4505919	W	Based on		WO 9015152
HU 61341	T	Based on		WO 9015152
AU 657255	B	Previous Publ.		AU 9057258
		Based on		WO 9015152
EP 474691	B1	Based on		WO 9015152
		Designated States (Regional): AT BE CH DE DK ES FR GB IT LI LU NL SE		
DE 69029134	E	Based on		EP 474691
		Based on		WO 9015152
ES 2096588	T3	Based on		EP 474691
US 5690933	A	Cont of	US 91768868	
		Cont of	US 9347344	
		Cont of	US 94181170	

Language, Pages: EP 474691 (44); ZA 9004174 (57); JP 4505919 (19); EP 474691 (E, 32); US 5690933 (23)
? ds

Set	Items	Description
S1	312	(NON(W)DEPLET? OR NONDEPLET?) AND (ANTIBOD? OR IMMUNOGLOBULIN?)
S2	224	S1 AND CD4
S3	67	S2 AND HUMAN?
S4	45	RD S3 (unique items)

? s s1 and cd8

```
            312  S1
          61088  CD8
      S5     95  S1 AND CD8
```

? rd s5

>>>Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.
...examined 50 records (50)
...completed examining records
S6 42 RD S5 (unique items)
? s s2 and review?

224 S2
2149145 REVIEW?
S7 6 S2 AND REVIEW?
? t s7/3/all

7/3/1 (Item 1 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

11922318 BIOSIS Number: 98522318
Therapeutic monoclonal **antibodies**
Choy E H S; Panayi G S; Kingsley G H
Rheumatol. Unit, Div. Medicine, UMDS, 4th Floor, Hunt's House, Guy's Hospital, St. Thomas Street, London SE1 9RT, UK
British Journal of Rheumatology 34 (8). 1995. 707-715.
Full Journal Title: British Journal of Rheumatology
ISSN: 0263-7103
Language: ENGLISH
Print Number: Biological Abstracts Vol. 100 Iss. 011 Ref. 173175

7/3/2 (Item 1 from file: 72)
DIALOG(R)File 72:EMBASE

10623307 EMBASE No: 98050169
Clinical pharmacology and therapeutic potential of monoclonal **antibody** treatment in rheumatoid arthritis
Choy E.H.S.
Dr. E.H.S. Choy, Rheumatology Unit, Thomas Guy House, Guy's Hospital, St Thomas Street, London SE1 9RT United Kingdom
Drugs and Aging (New Zealand) , 1998, 12/2 (139-148)
CODEN: DRAGE ISSN: 1170-229X
DOCUMENT TYPE: Journal Review
LANGUAGES: ENGLISH SUMMARY LANGUAGES: ENGLISH
NUMBER OF REFERENCES: 51

7/3/3 (Item 2 from file: 72)
DIALOG(R)File 72:EMBASE

9787616 EMBASE No: 95351540
T-cell regulation
Choy E.H.S.; Kingsley G.H.; Panayi G.S.
UMDS, Rheumatology Unit, Guy's Hospital, St Thomas Street, London SE1 9RT United Kingdom
Bailliere's Clinical Rheumatology (United Kingdom) , 1995, 9/4 (653-671)
CODEN: BCRHE ISSN: 0950-3579
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/4 (Item 3 from file: 72)
DIALOG(R)File 72:EMBASE

(c) 1998 Elsevier Science B.V. All rts. reserv.

9737958 EMBASE No: 95293479
Therapeutic monoclonal **antibodies**
Choy E.H.S.; Panayi G.S.; Kingsley G.H.
Rheumatology Unit, Division of Medicine, UMDS, Guy's Hospital, St Thomas Street, London SE1 9RT United Kingdom
British Journal of Rheumatology (United Kingdom) , 1995, 34/8 (707-715)
CODEN: BJRHD ISSN: 0263-7103
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/5 (Item 4 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1998 Elsevier Science B.V. All rts. reserv.

8675097 EMBASE No: 92355607
Anti-**CD4** monoclonal **antibodies** in therapy: Creation of nonclassical tolerance in the adult
Shizuru J.A.; Alters S.E.; Fathman C.G.
Stanford Univ. School of Medicine, Div. of Rheumatology and Immunology, Stanford, CA 94305 USA
IMMUNOL. REV. (Denmark) , 1992, -/129 (105-130)
CODEN: IMRED ISSN: 0105-2896 ADONIS ORDER NUMBER: 010528969200046X
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/6 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 1998 American Chemical Society. All rts. reserv.

128191337 CA: 128(16)191337j CONFERENCE PROCEEDING
The therapeutic potential of a primatized nondepleting anti-CD4 (IDEC-CE9.1) monoclonal antibody in rheumatoid arthritis
AUTHOR(S): Solinger, Alan M.; Truneh, Alemseged; Lipani, John A.; Newman, Roland A.
LOCATION: IDEC Pharmaceutical Corporation, San Diego, CA, USA
JOURNAL: Antibody Ther. EDITOR: Harris, William J. (Ed), Adair, John R (Ed), DATE: 1997 PAGES: 341-353 CODEN: 65RLAP LANGUAGE: English
PUBLISHER: CRC,Boca Raton, Fla
? s s6 and human?

Processing
42 S6
9670595 HUMAN?
S8 10 S6 AND HUMAN?
? rd s8

>>>Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.
...completed examining records
S9 10 RD S8 (unique items)
? t s9/7/all

9/7/1 (Item 1 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1998 BIOSIS. All rts. reserv.

11345669 BIOSIS Number: 97545669
Immunological approach to inhibit formation of anti-**antibodies** to allo- and xenogeneic anti-T cell **immunoglobulin**
Mysliwietz J; Thierfelder S; Mocikat R; Kremmer E
GSF, Inst. Immunol., Marchioninistr. 25, D-81377 Muenchen, GER

European Journal of Immunology 24 (10). 1994. 2323-2328.
Full Journal Title: European Journal of Immunology
ISSN: 0014-2980
Language: ENGLISH
Print Number: Biological Abstracts Vol. 098 Iss. 012 Ref. 163292

Inhibitory anti-**antibodies** induced in patients by xenogeneic or even by **humanized** anti-T cell **antibodies** remain an unresolved problem. Mice also produce anti-**antibodies** following injection of xeno- or allogeneic anti-T cell **antibodies** . Here we report a principle based on sequentially applied anti-T cell **antibodies** generated in different species, which results in suppressed anti-**antibody** formation and prolonged immunosuppression. Thus, a single priming injection in mice of mouse (MmT1 or MmT5 differing by idiotype only) or of rat (RmT1) anti-mouse Thy-1 monoclonal **antibodies** (mAb) or of rat anti-mouse L3T4 + Ly-2 (RmCD4 + **CD8**) mAb suppressed anti-**antibody** formation against subsequent booster injections of one of the above **antibodies**, provided that they differed in species origin from the priming **antibody** . Correspondingly, a sixfold and longer prolongation of 50 % survival of fully mismatched skin grafts was observed. Less or no anti-**antibody** suppression and little prolongation of graft survival was obtained if the 'first' and the 'second' (and following) **antibody** injections were of the same species, differing by iso- or idiotype only. Finally, the suppressive principle did not manifest itself at all if the initial **antibody** injection included both the first and second **antibody** . These findings are discussed with reference to earlier studies on hapten/carrier effects as well as on immunosuppression attributed to **'non-depleting'** rat anti-CD4/**CD8** T cell **antibodies**.

9/7/2 (Item 2 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

10805769 BIOSIS Number: 97005769

T-cell recognition of a cross-reactive antigen(s) in erythrocytic stages of Plasmodium falciparum and Plasmodium yoelii: Inhibition of parasitemia by this antigen(s)

Lucas B; Engels A; Camus D; Haque A
Centre Immunol., Biol. Parasitaire, Inst. Pasteur, 59019 Lille, FRA
Infection and Immunity 61 (11). 1993. 4863-4869.
Full Journal Title: Infection and Immunity
ISSN: 0019-9567
Language: ENGLISH
Print Number: Biological Abstracts Vol. 097 Iss. 001 Ref. 005267

In the current study, we investigated the presence of a cross-reactive antigen(s) in the erythrocyte stage from Plasmodium yoelii (265 BY strain) and Plasmodium falciparum through recognition by T cells primed in vivo with antigens from each of these parasites. BALB/c mice are naturally resistant to P. falciparum but are susceptible to P. yoelii infection. Mice that had recovered from P. yoelii primary infection became resistant to a second infection. A higher in vitro proliferative response to a soluble blood stage preparation of P. falciparum was observed in splenic cells from immune animals than in those from mice with a patent P. yoelii infection. The antigen-induced proliferative response was enhanced when animals were exposed to a secondary infection. Animals exposed to a challenge infection were treated with anti-CD4 or anti-**CD8** monoclonal **antibodies** to deplete the corresponding subset of T cells. There was a marked diminution in P. falciparum antigen-induced proliferative response in the total splenic cell populations from **CD8**-depleted but not from CD4-depleted mice. In **CD8**-depleted and **nondepleted** animals, the antigen-induced proliferation in the total cell populations was markedly lower than in the T-cell-rich populations, indicating inhibitory activities of B cells and/or macrophages. There was no such difference in the stimulation between total and T-enriched cell populations from CD4-depleted

animals. Flow cytometry analysis demonstrated the presence of an almost equal percentage of **CD8**+ (59.6%) and CD4+ (64%) T cells in the spleen preparations following in vivo depletion of CD4- and **CD8**-bearing T cells, respectively. When cultured with P. yoelii blood stage antigen, splenocytes from animals immunized with P. falciparum antigen displayed a significant proliferative response which was markedly diminished by treatment with anti-Thy-1.2 **antibody** plus complement. Animals immunized with P. falciparum antigen and then challenged with P. yoelii blood stage parasites displayed about a 50% lower level of parasitemia. These results demonstrated the existence of a cross-reactive antigen(s) between a murine and a **human** Plasmodium species, as determined from both in vivo and in vitro biological assays, and indicated the reactivity of mainly **CD8**+ T cells with this antigen.

9/7/3 (Item 3 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

7083977 BIOSIS Number: 88006722
ENDOGENOUSLY GENERATED ACTIVATED KILLER CELLS CIRCULATE AFTER AUTOLOGOUS AND ALLOGENEIC MARROW TRANSPLANTATION BUT NOT AFTER CHEMOTHERAPY
REITTIE J E; GOTTLIEB D; HESLOP H E; LEGER O; DEXLER H G; HAZLEHURST G; HOFFBRAND A V; PRENTICE H G; BRENNER M K
DEP. HAEMATOL., ROYAL FREE HOSP., POND ST., LONDON, NW3, UK.
BLOOD 73 (5). 1989. 1351-1358. CODEN: BLOOA
Full Journal Title: Blood
Language: ENGLISH
After marrow transplantation, major histocompatibility complex (MHC)-unrestricted natural killer (NK) lymphocytes are among the first cells to appear in the circulation. After T-cell-depleted bone marrow transplantation (TD-BMT), these cells have an activated pattern of target cell killing; they also secrete lymphokines including .gamma.-interferon (.gamma.-IFN), interluekin-2 (IL-2), and tumor necrosis factor (TNF) and may have a significant role as a primary defense against viral reactivation and in the elimination of residual host malignancy. We studied 43 patients with hematologic malignancy, treated by allogeneic TD-BMT, autologous **nondepleted** BMT, or chemotherapy alone to investigate (a) the mechanisms underlying the generation of these activated killer cells, (b) the range of conditions under which they are produced, and (c) their surface phenotype. We showed that .gamma.-IFN-secreting activated killer cells with the capacity to kill MHC-nonidentical NK-resistant targets are generated 4 to 6 weeks after either allogeneic TD-BMT or autologous BMT but do not appear after treatment with chemotherapy. Production therefore is not owing to T-cell depletion per se or to host donor alloreactivity, nor is it caused by stimulation by alloantigens contained in blood product support since no significant difference exists between allograft and chemotherapy patients in the number of units of blood platelet support given in the posttreatment period. Because most patients had no evidence of stimulation from virus reactivation/infection, the phenomenon of activation therefore appears to represent posttransplant immune disregulation following repopulation of the host immune system with lymphoid subsets derived exclusively from blood and marrow. Activated killing is predominantly mediated by the CD16+ CD3- subset, but substantial activity remains in the CD16- CD3+ cell fraction. Monoclonal **antibodies** (MoAbs) that block interaction with class-I MHC molecules at the level of target cell (W6/32 anti-HLA class I) or effector cell (**CD8**) do not inhibit killing by CD16- CD3+ cells. Activated killer cells may contribute to the lower risk of relapse after marrow transplantation as compared with intensive chemotherapy.

9/7/4 (Item 4 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

5856041 BIOSIS Number: 83118348
A COMPARATIVE STUDY OF T-CELL DEPLETED AND **NON-DEPLETED** MARROW TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY
ATKINSON K; ASHBY M; BIGGS J; CONCANNON A; COOLEY M; DODDS A; FARRELLY H; MORGAN G; O'FLAHERTY E; ET AL
BONE MARROW TRANSPLANT. UNIT, ST. VICENT'S HOSP., DARLINGHURST, NSW 2010.
AUST N Z J MED 17 (1). 1987. 16-23. CODEN: ANZJB
Full Journal Title: Australian and New Zealand Journal of Medicine
Language: ENGLISH
Sixteen patients with hematological malignancy received cyclophosphamide (120 mg/kg), fractionated total body irradiation (12 Gy), oral cyclosporin, and an HLA-identical sibling marrow transplant depleted of T cells by incubation with the monoclonal **antibody** antiHuLy-m1 (CD2) and rabbit complement with (five patients) or without (11 patients) anti-HuLy-m8 (**CD8**). These 16 patients were compared historically to 84 patients with hematological malignancy receiving cyclophosphamide (120 mg/kg), fractionated total body irradiation (12 or 14 Gy), oral cyclosporin, and unmanipulated HLA-identical sibling marrow, for parameters of engraftment and graft-versus-host disease (GVHD). Graft failure occurred in one of the 16 T-cell depleted recipients and in one of the 84 **non-depleted** recipients. Engraftment was slightly but significantly slower in the T-cell depleted group and bacterial infections significantly more frequent and severe than in the unmanipulated group. There was a suggestion that the severity of acute GVHD was reduced in those receiving T depleted marrow. Randomized trials will be necessary to determine if marrow T-cell depletion results in superior long-term leukemia-free survival.

9/7/5 (Item 1 from file: 72)
DIALOG(R)File 72:EMBASE

8675097 EMBASE No: 92355607
Anti-CD4 monoclonal **antibodies** in therapy: Creation of nonclassical tolerance in the adult
Shizuru J.A.; Alters S.E.; Fathman C.G.
Stanford Univ. School of Medicine, Div. of Rheumatology and Immunology, Stanford, CA 94305 USA
IMMUNOL. REV. (Denmark) , 1992, -/129 (105-130)
CODEN: IMRED ISSN: 0105-2896 ADONIS ORDER NUMBER: 010528969200046X
LANGUAGES: English SUMMARY LANGUAGES: English
We have described the studies from our laboratory which demonstrate that depleting anti-CD4 mAb induce tolerance to foreign antigens in adult, euthymic animals. Further, we have proposed that such tolerance occurs as a result of new thymic migrants encountering antigens in the periphery. However, these conclusions can be considered only partial since we (Song et al. in press) and others have shown that depletion of T cells per se does not permit tolerance. For example, anti-Thy-1 or anti-Lyt-1 are themselves immunosuppressive and able to deplete T cells, yet they elicit strong anti-globulin responses against themselves and do not permit tolerance to be induced either to transplants or administered soluble protein antigen. We have recently found that while the combination of anti-CD4 and anti-**CD8** mAb allows long-term survival of allografted islets in mice, anergy in the relevant T-cell subsets was not found (in contrast to what is found with anti-CD4 mAb treatment alone) (Song et al. in press). In this instance, long-term survival was probably the result of changes in graft immunogeneity (i.e., migration of passenger leukocytes) since the kinetics of repopulation were much delayed in the anti-CD4 and -**CD8** treated mice. As discussed elsewhere in this volume, interesting studies from several laboratories suggest that **non-depleting** anti-CD4 mAb can generate unresponsiveness in a variety of systems. In reviewing the literature it is clear that the success of **non-depleting** reagents appears to be dependent upon the model system tested. For example, although depleting and **nondepleting** CD4 mAb regimens produced

comparable prolongation of cultured fetal pancreas allografts in mice (Charlton and Mandel), almost total elimination of circulating CD4+ cells did not prevent acute rejection of murine skin grafts (Auchincloss et al. 1988). This heterogeneity is not surprising given the multiple functional roles of the CD4 molecule and the cells that bear this molecule. In addition to depletion, **antibodies** directed against CD4 can potentially affect CD4+ cell function by (1) direct blockade or failure to augment the formation of the TCR-antigen/MHC ternary complex or (2) by transmitting a negative signal to the CD4 T cell or interfering with normal signal transduction mechanisms. Undoubtedly, it is a combination of mechanisms that allows these **antibodies** their immunosuppressive effects. What can be said with certainty is that these **antibodies** will continue to be important tools for understanding the molecular and cellular basis of the immune response, and will soon emerge as invaluable therapeutic agents in the clinical arena.

9/7/6 (Item 2 from file: 72)
DIALOG(R)File 72:EMBASE

8183556 EMBASE No: 91209639
Monoclonal **antibody** therapy for the induction of transplantation tolerance
Cobbold S.P.
Division of Immunology, Cambridge University Department of Pathology, Tennis Court Road, Cambridge CB1 2QP United Kingdom
IMMUNOL. LETT. (Netherlands) , 1991, 29/1-2 (117-122)
CODEN: IMLED ISSN: 0165-2478 ADONIS ORDER NUMBER: 016524789100175N
LANGUAGES: English
There are three ways in which monoclonal **antibodies** could be used to facilitate the induction of tolerance to foreign tissues after organ transplantation. First, depleting monoclonal **antibodies** could be directed against the T cells responsible, thereby reducing their number and acting to non-specifically immunosuppress the patient. This is generally not sufficient to allow tolerance induction in the T cells which repopulate the periphery. Second, depleting monoclonal **antibodies** could be used to remove donor passenger leukocytes and antigen-presenting cells from the donor organ, which may both reduce immunogenicity and increase the chance of tolerance induction. Third, **non-depleting**, but functionally blocking, monoclonal **antibodies** to T cell molecules such as CD4 and **CD8** can allow the specific induction of transplantation tolerance in mouse models, an approach which might be applicable to man, not only for organ transplantation, but also in the treatment of autoimmune diseases. These three approaches are, in time, likely to complement each other in clinical practice. Monoclonal **antibodies** can be tailored to each approach by choosing appropriate specificities and isotypes, and further refinements can be made where necessary by making monovalent or **humanised antibodies** . The application of each of these approaches to clinical therapy is described.

9/7/7 (Item 3 from file: 72)
DIALOG(R)File 72:EMBASE

8013038 EMBASE No: 91038466
Induction of tolerance in peripheral T cells with monoclonal **antibodies**
Qin S.; Wise M.; Cobbold S.P.; Leong L.; Kong Y.-C.M.; Parnes J.R.; Waldmann H.
Division of Immunology, Department of Pathology, Cambridge University, Cambridge CB2 2QQ United Kingdom
EUR. J. IMMUNOL. (Germany, Federal Republic of) , 1990, 20/12 (2737-2745)
CODEN: EJIMA ISSN: 0014-2980

LANGUAGES: English

Our goal has been to develop ways to tolerize the mature immune system to any defined antigen. In this report we show that peripheral (post-thymic) T cells of mice can become tolerant to a range of antigens (**human** and rat **immunoglobulins** , and bone marrow and skin grafts that differ at multiple minor transplantation antigens). In the case of **human** gamma globulin (HGG), this required that the antigen be given under the cover of a short course of **non-depleting** anti-CD4 **antibody**, while for tolerance to skin and marrow grafts anti-**CD8 antibody** was also required. Tolerance to HGG could be reinforced by repeated injections of HGG, but was lost in the absence of any further exposure to antigen. This reversal of tolerance with time was due to new T cells being exported from the thymus, as it was not observed in tolerized, adult thymectomized mice. In contrast, tolerance to marrow and skin grafts was permanent, presumably because the established grafts acted as a continuous source of antigen to reinforce the tolerant state. Tolerance could not be broken by the infusion of unprimed spleen cells and in one example (tolerance to Mls-1a) there was clear evidence that specific peripheral T cells were anergic. We propose that anergic cells may themselves participate in reinforcing the tolerant state by competing at sites of antigen presentation.

9/7/8 (Item 1 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

09426656 98149797

Treatment of recalcitrant plaque psoriasis with a **humanized non-depleting antibody** to CD4.

Bachelez H; Flageul B; Dubertret L; Fraitag S; Grossman R; Brousse N; Poisson D; Knowles RW; Wacholtz MC; Haverty TP; Chatenoud L; Bach JF

Service Dermatologie, Hopital Saint-Louis, Paris, France.

J Autoimmun (ENGLAND) Feb 1998, 11 (1) p53-62, ISSN 0896-8411
Journal Code: ADL

Languages: ENGLISH

Document type: JOURNAL ARTICLE

The presence of activated CD4(+) T lymphocytes in psoriatic skin plaques suggests an immune-mediated pathogenesis for the disease. Six patients with recalcitrant plaque psoriasis (PASI>12) received a **humanized non-depleting** monoclonal **antibody** to CD4 (ORTHOCLONE OKT(R)cdr4a). The **antibody** was well tolerated. Four weeks from treatment, the mean decrease in PASI score was 46%. In three patients disease remission was prolonged for up to 6 months and, in one case, up to 1 year post-treatment. In all patients, circulating CD4+ T-cell counts remained normal and peripheral OKTcdr4a-coated CD4+ lymphocytes were detected up to 10 days after **antibody** infusion. These results point to the relevance of CD4+ lymphocytes in psoriasis. They also emphasize that depletion of CD4+ cells is not mandatory to achieve therapeutic effectiveness.

9/7/9 (Item 2 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

06603039 91370929

Reprogramming the immune system for tolerance with monoclonal **antibodies**.

Cobbold SP; Qin SX; Waldmann H

Department of Pathology, Cambridge University, UK.

Semin Immunol (UNITED STATES) Nov 1990, 2 (6) p377-87, ISSN 1044-5323
Journal Code: A61

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

Monoclonal **antibodies** to CD4, **CD8** and CD11a can be used in vivo either to deplete or functionally block T cells to create a tolerance permissive environment. Short courses of **non-depleting** CD4 and **CD8 antibodies** were used to induce tolerance separately in CD4+ and **CD8**+ T cells either to foreign **immunoglobulins**, bone marrow, or skin grafts. Tolerance was obtained to minor (non-MHC) transplantation antigens without T cell depletion even in actively sensitized mice, or to MHC plus minor antigens presented directly by skin grafts using combinations of depleting followed by blockading CD4 and **CD8 antibodies** . In all cases, tolerance was specific to the antigen/tissue given under cover of **antibody** treatment, and in one example it could be shown that T cells directed to MLS-1a had been forced into an anergic state. This induction of tolerant, anergic T cells in the periphery is able to explain many of the features associated with tolerance, not only in the model systems using foreign antigens, but also in the normal regulation of anti-self responses and its failure in autoimmune diseases. It is our new found ability to use antigen under the cover of **antibody** treatment to accurately control the pattern of tolerant T cells in vivo that we refer to by using the term 'reprogramming'. We also describe the clinical treatment of one patient with an autoimmune vasculitis based on the ideas developed from the mouse models. (47 Refs.)

9/7/10 (Item 1 from file: 351)
DIALOG(R)File 351:DERWENT WPI

008503137
WPI Acc No: 91-007221/199101
Non-depleting CD4 and **CD8** monoclonal **antibodies** - for inducting tolerance to foreign antigens in transplant rejection, auto-immune disease, etc
Patent Assignee: COBBOLD S P (COBB-I); WALDMANN H (WALD-I); WELLCOME FOUND LTD (WELL); GLAXO WELLCOME INC (GLAX)
Inventor: COBBOLD S P; WALDMANN H
Number of Countries: 025 Number of Patents: 015
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
WO 9015152	A	19901213					199101 B
PT 94214	A	19910208					199109
AU 9057258	A	19910107					199115
EP 474691	A	19920318	EP 90908270	A	19900531		199212
ZA 9004174	A	19920226	ZA 904174	A	19900530		199213
DD 296843	A5	19911219	DD 341218	A	19900531	A61K-039/395	199221
JP 4505919	W	19921015	JP 90508030	A	19900531	A61K-039/395	199248
			WO 90GB840	A	19900531		
HU 61341	T	19921230	HU 905134	A	19900531	C12P-021/08	199306
			WO 90GB840	A	19900531		
AU 657255	B	19950309	AU 9057258	A	19900531	C12P-021/08	199520
EP 474691	B1	19961113	EP 90908270	A	19900531	C12P-021/08	199650
			WO 90GB840	A	19900531		
DE 69029134	E	19961219	DE 629134	A	19900531	C12P-021/08	199705
			EP 90908270	A	19900531		
			WO 90GB840	A	19900531		
ES 2096588	T3	19970316	EP 90908270	A	19900531	C12P-021/08	199718
NZ 233889	A	19970624	NZ 233889	A	19900531	A61K-039/395	199732
BR 1100287	A3	19970916	BR 971100287	A	19970415	C12P-021/08	199744
US 5690933	A	19971125	US 91768868	A	19910727	A61K-039/395	199802
			US 9347344	A	19930329		
			US 94181170	A	19940113		
			US 94289532	A	19940812		

Priority Applications (No Type Date): GB 8912497 A 19890531
Cited Patents: 4.Jnl.Ref

Patent Details:

Patent	Kind	Lan	Pg	Filing Notes	Application	Patent
WO 9015152	A					
Designated States (National): AU CA FI HU JP KR US						
Designated States (Regional): AT BE CH DE DK ES FR GB IT LU NL SE						
EP 474691	A		44			
Designated States (Regional): AT BE CH DE DK ES FR GB IT LI LU NL SE						
ZA 9004174	A		57			
JP 4505919	W		19	Based on		WO 9015152
HU 61341	T			Based on		WO 9015152
AU 657255	B			Previous Publ.		AU 9057258
				Based on		WO 9015152
EP 474691	B1	E	32	Based on		WO 9015152
Designated States (Regional): AT BE CH DE DK ES FR GB IT LI LU NL SE						
DE 69029134	E			Based on		EP 474691
				Based on		WO 9015152
ES 2096588	T3			Based on		EP 474691
US 5690933	A		23	Cont of	US 91768868	
				Cont of	US 9347344	
				Cont of	US 94181170	

Abstract (Basic): WO 9015152 A

Non depleting CD4 and **CD8** monoclonal **antibodies** are claimed for use in inducing tolerance to an antigen. The use of these **antibodies** and packs contg. them are also claimed. The prods. may also contain a depleting CD4 monoclonal **antibody** and/or a depleting **CD8** monoclonal **antibody**.

Single dose for a **human** is 1-400mg (esp. 3-30mg) of **antibody**. Admin. is parenteral e.g. intravenous.

USE/ADVANTAGE - For producing tolerance to foreign **immunoglobulins**, bone marrow and skin grafts. To treat autoimmune diseases without the need for long term chemotherapy and to produce tolerance to therapeutic polypeptides such as interferon, IL-II or TNF. (44pp Dwg.No.0/13)

Abstract (Equivalent): EP 474691 B

Use of a **non-depleting** anti-CD4 monoaconal **antibody**, ie an **antibody** which causes depletion of fewer than 50% of CD4+ T-cells from the periphery as measured by changes in the peripheral blood lymphocyte numbers, for the manufacture of a medicament for the induction of a state of immunological tolerance to an antigen by a method which comprises administering said **non-depleting** anti-CD4 monoclonal **antibody** to a subject together with a **non-depleting** anti-**CD8** monoclonal **antibody**, ie an **antibody** which causes depletion of fewer than 50% of **CD8**+ T-cells from the periphery as measured by changes in the peripheral blood lymphocyte numbers, to induce an immunological tolerance permissive environment within said subject by means of said **antibodies** in the presence of said antigen.

(Dwg.0/11b

Abstract (Equivalent): US 5690933 A

Non depleting CD4 and **CD8** monoclonal **antibodies** are claimed for use in inducing tolerance to an antigen. The use of these **antibodies** and packs contg. them are also claimed. The prods. may also contain a depleting CD4 monoclonal **antibody** and/or a depleting **CD8** monoclonal **antibody**.

Single dose for a **human** is 1-400mg (esp. 3-30mg) of **antibody**. Admin. is parenteral e.g. intravenous.

USE/ADVANTAGE - For producing tolerance to foreign **immunoglobulins**, bone marrow and skin grafts. To treat autoimmune diseases without the need for long term chemotherapy and to produce tolerance to therapeutic polypeptides such as interferon, IL-II or TNF.

Dwg.0/13b

Derwent Class: B04; D16

International Patent Class (Main): A61K-039/395; C12P-021/08

International Patent Class (Additional): A61K-037/02; A61K-039/39;

C07K-015/28; C07K-016/24; C07K-016/42; C12N-015/00; G01N-000/00
? ds

```
Set     Items   Description
S1        312   (NON(W)DEPLET? OR NONDEPLET?) AND (ANTIBOD? OR IMMUNOGLOBU-
                LIN?)
S2        224   S1 AND CD4
S3         67   S2 AND HUMAN?
S4         45   RD S3 (unique items)
S5         95   S1 AND CD8
S6         42   RD S5 (unique items)
S7          6   S2 AND REVIEW?
S8         10   S6 AND HUMAN?
S9         10   RD S8 (unique items)
? s s2 and py=1988

             224  S2
         2151700  PY=1988
     S10       3  S2 AND PY=1988
? rd s10

>>>Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.
...completed examining records
     S11       1  RD S10 (unique items)
? t s11/3/all


 11/3/1     (Item 1 from file: 55)
DIALOG(R)File  55:BIOSIS PREVIEWS(R)
(c) 1998 BIOSIS. All rts. reserv.

7010730     BIOSIS Number: 87071251
  ADOPTIVE IMMUNITY IN IMMUNE-DEFICIENT SCID-SCID MICE I. DIFFERENTIAL
REQUIREMENTS OF NAIVE AND PRIMED LYMPHOCYTES FOR CD4-POSITIVE T CELLS
DURING REJECTION OF MINOR HISTOCOMPATIBILITY ANTIGEN-DISPARATE SKIN GRAFTS
  ROOPENIAN D C; ANDERSON P S
  JACKSON LAB., BAR HARBOR, ME 04609.
  TRANSPLANTATION (BALTIMORE) 46 (6). 1988.  899-904.   CODEN: TRPLA
  Full Journal Title:  TRANSPLANTATION (Baltimore)
  Language: ENGLISH
? s s2 and py=1989

             224  S2
         2238453  PY=1989
     S12       9  S2 AND PY=1989
? rd s12

>>>Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.
...completed examining records
     S13       3  RD S12 (unique items)
? t s13/3/all


 13/3/1     (Item 1 from file: 55)
DIALOG(R)File  55:BIOSIS PREVIEWS(R)
(c) 1998 BIOSIS. All rts. reserv.

7185784     BIOSIS Number: 88108529
  ENGAGEMENT OF CD-4 AND CD-8 ACCESSORY MOLECULES IS REQUIRED FOR T CELL
MATURATION
```

RAMSDELL F; FOWLKES B J
LAB. CELLULAR MOLECULAR IMMUNOL., NIAID, NIH, BUILDING 4, ROOM 111, BETHESDA, MD 20892.
J IMMUNOL 143 (5). 1989. 1467-1471. CODEN: JOIMA
Full Journal Title: Journal of Immunology
Language: ENGLISH

13/3/2 (Item 2 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1998 BIOSIS. All rts. reserv.

7104252 BIOSIS Number: 88026997
AN INCREASE IN THE SURVIVAL OF MURINE H-2-MISMATCHED CULTURED FETAL PANCREAS ALLOGRAFTS USING DEPLETING OR **NONDEPLETING** ANTI-**CD4** MONOCLONAL **ANTIBODIES** AND A FURTHER INCREASE WITH THE ADDITION OF CYCLOSPORINE
BURKHARDT K; CHARLTON B; MANDEL T E
TRANSPANTATION UNIT, WALTER AND ELIZA HALL INST. MED. RES., POST OFFICE, ROYAL MELBOURNE HOSP., VICTORIA 3050, AUST.
TRANSPLANTATION (BALTIMORE) 47 (5). 1989. 771-775. CODEN: TRPLA
Full Journal Title: TRANSPLANTATION (Baltimore)
Language: ENGLISH

13/3/3 (Item 3 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1998 BIOSIS. All rts. reserv.

7010433 BIOSIS Number: 87070954
T-CELL-MEDIATED PROTECTION OF MICE AGAINST VIRULENT MYCOBACTERIUM-TUBERCULOSIS
LEVETON C; BARNASS S; CHAMPION B; LUCAS S; DE SOUZA B; NICOL M; BANERJEE D; ROOK G
DEP. MED. MICROBIOL., UNIV. COLL., LONDON W1P 7PP, U.K.
INFECT IMMUN 57 (2). 1989. 390-395. CODEN: INFIB
Full Journal Title: Infection and Immunity
Language: ENGLISH
? s s2 and py=1987

```
            224  S2
        2075095  PY=1987
    S14       2  S2 AND PY=1987
? rd s14

>>>Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.
...completed examining records
    S15       1  RD S14 (unique items)
? t s15/3/all
```

15/3/1 (Item 1 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1998 BIOSIS. All rts. reserv.

5934551 BIOSIS Number: 84067116
CD4 POSITIVE T CELLS APPEAR CAPABLE OF INITIATING GRAFT-VERSUS-HOST DISEASE ACROSS NON-MAJOR HISTOCOMPATIBILITY COMPLEX MHC BARRIERS IN MAN
ATKINSON K; COOLEY M; FARRELLY H; O'FLAHERTY E; ASHBY M; BIGGS J
DEP. HAEMATOL., ST VINCENT'S HOSP., DARLINGHURST, NSW 2010, AUSTRALIA.
BONE MARROW TRANSPLANT 2 (1). 1987. 79-84. CODEN: BMTRE
Full Journal Title: Bone Marrow Transplantation
Language: ENGLISH

? s s2 and py=1990

```
            224  S2
        2373119  PY=1990
    S16      11  S2 AND PY=1990
? rd s16

>>>Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.
...completed examining records
    S17       6  RD S16 (unique items)
? t s17/7/all
```

17/7/1 (Item 1 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1998 BIOSIS. All rts. reserv.

8167526 BIOSIS Number: 91088526
THE INDUCTION OF SKIN GRAFT TOLERANCE IN MAJOR HISTOCOMPATIBILITY COMPLEX-MISMATCHED OR PRIMED RECIPIENTS PRIMED T CELLS CAN BE TOLERIZED IN THE PERIPHERY WITH ANTI-**CD4** AND ANTI-CD8 **ANTIBODIES**
COBBOLD S P; MARTIN G; WALDMANN H
DIV. IMMUNOL., CAMBRIDGE UNIV., DEP. PATHOL., LEVEL 3 LAB. BLOCK, NEW ADDENBROOKES HOSP., CAMBRIDGE CB2 2QQ, GREAT BRITIAN.
EUR J IMMUNOL 20 (12). 1990. 2747-2756. CODEN: EJIMA
Full Journal Title: European Journal of Immunology
Language: ENGLISH
Mice given short courses of anti-**CD4** and anti-CD8 monoclonal **antibodies** became tolerant of allogeneic skin grafted at the same time. Tolerance could be obtained without T cell depletion across multiple minor antigen mismatches, both in native and primed animals, demonstrating that peripheral T cells could be tolerized, even if they had been previously activated. Where donor and recipient were incompatible across the whole major histocompatibility complex, specific tolerance could be achieved by using a combination of depleting following by **non-depleting antibodies** , where each alone was unsuccessful. Although mice clearly tolerated their original skin grafts, we observed in some strain combinations that a second fresh, but genotypically indentical graft, was slowly rejected. Such mice also possessed T cells which could proliferate to donor-type stimulator cells in vtiro. Whatever the mechanisms, we have demonstrated that operational transplantation tolerance can be achieved with simple, non-toxic **antibody** therapy. The introduction of comparable tolerance-inducing regimens in clinical organ transplantation could obviate the need for long-term immunosuppression and its unfortunate side effects.

17/7/2 (Item 2 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1998 BIOSIS. All rts. reserv.

8095291 BIOSIS Number: 91016291
RESISTANCE TO INFECTION BY HIV-1 OF PERIPHERAL BLOOD MONONUCLEAR CELLS FROM HIV-1-INFECTED PATIENTS IS PROBABLY MEDIATED BY NEUTRALIZING **ANTIBODIES**
TREMBLAY M; NUMAZAKI K; LI X; GORNITSKY M; HISCOTT J; WAINBERG M A
MCGILL AIDS CENTRE JEWISH GENERAL HOSP., 3755 COTE STE-CATHERINE ROAD, MONTREAL, QUEBEC H3T 1E2, CAN.
J IMMUNOL 145 (9). 1990. 2896-2901. CODEN: JOIMA
Full Journal Title: Journal of Immunology
Language: ENGLISH
We have investigated whether PBMC of HIV-1-seropositive subjects are as susceptible to in vitro infection by HIV-1 as are PBMC from seronegative

controls. Accordingly, stimulated PBMC from 19 HIV-1-infected subjects were inoculated with four different variants of HIV-1. None of these cultures produced either detectable quantitites of viral reverse transcriptase activity or p24 Ag following inoculation with HIV-1. In contrast, in five of six cases in which these PBMC were depleted of B cells by **antibody** plus complement prior to viral inoculation, the presence of viral reverse transcriptase and p24 Ag was detected. The presence of normal levels of **CD4** Ag at the surface of the **CD4**+ cells in these populations was established by flow cytometry. Analysis by an immunoblot assay revealed that anti-HIV **antibodies** were present in the sera obtained from these infected donors; in addition, 7 of 10 culture fluids derived from the **nondepleted** PBMC were shown to contain virus-neutralizing **antibodies** . Cultures which were depleted of B cells did not contain detectable levels of antiviral **antibodies** . Confirmation that the virus produced by the PBMC which had been depleted of B cells was of the strain used to infect the cultures, rather than that which initially caused patient infection, was provided on the basis of differential susceptibility to **antibody** neutralization. These results suggest that **antibodies** produced by B cells in cultures of PBMC from seropositive donors may restrict infection by HIV-1 of such cultures under laboratory conditions.

17/7/3 (Item 3 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

7529494 BIOSIS Number: 39042101
A **NONDEPLETING** RAT **CD4** MONOCLONAL **ANTIBODY** MAB INHIBITS **CD4**-POSITIVE SUPPRESSOR-MEDIATED RESISTANCE TO MURINE EXPERIMENTAL AUTO-IMMUNE THYROIDITIS EAT IN-VIVO
NABOZNY G H; COBBOLD S; WALDMANN H; KONG Y M
WAYNE STATE UNIV. SCH. MED., DETROIT, MICH. 48201.
JOINT MEETING OF THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, AND THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, NEW ORLEANS, LOUISIANA, USA, JUNE 4-7, 1990. FASEB (FED AM SOC EXP BIOL) J 4 (7). 1990. A2099. CODEN: FAJOE
Language: ENGLISH

17/7/4 (Item 1 from file: 72)
DIALOG(R)File 72:EMBASE

8013038 EMBASE No: 91038466
Induction of tolerance in peripheral T cells with monoclonal **antibodies**
Qin S.; Wise M.; Cobbold S.P.; Leong L.; Kong Y.-C.M.; Parnes J.R.; Waldmann H.
Division of Immunology, Department of Pathology, Cambridge University, Cambridge CB2 2QQ United Kingdom
EUR. J. IMMUNOL. (Germany, Federal Republic of) , **1990**, 20/12 (2737-2745)
CODEN: EJIMA ISSN: 0014-2980
LANGUAGES: English
Our goal has been to develop ways to tolerize the mature immune system to any defined antigen. In this report we show that peripheral (post-thymic) T cells of mice can become tolerant to a range of antigens (human and rat **immunoglobulins** , and bone marrow and skin grafts that differ at multiple minor transplantation antigens). In the case of human gamma globulin (HGG), this required that the antigen be given under the cover of a short course of **non-depleting** anti-**CD4 antibody**, while for tolerance to skin and marrow grafts anti-CD8 **antibody** was also required. Tolerance to HGG could be reinforced by repeated injections of HGG, but was lost in the absence of any further exposure to antigen.

This reversal of tolerance with time was due to new T cells being exported from the thymus, as it was not observed in tolerized, adult thymectomized mice. In contrast, tolerance to marrow and skin grafts was permanent, presumably because the established grafts acted as a continuous source of antigen to reinforce the tolerant state. Tolerance could not be broken by the infusion of unprimed spleen cells and in one example (tolerance to Mls-1a) there was clear evidence that specific peripheral T cells were anergic. We propose that anergic cells may themselves participate in reinforcing the tolerant state by competing at sites of antigen presentation.

17/7/5 (Item 1 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

06603039 91370929
Reprogramming the immune system for tolerance with monoclonal **antibodies**.
Cobbold SP; Qin SX; Waldmann H
Department of Pathology, Cambridge University, UK.
Semin Immunol (UNITED STATES) Nov **1990**, 2 (6) p377-87, ISSN 1044-5323 Journal Code: A61
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
Monoclonal **antibodies** to **CD4**, CD8 and CD11a can be used in vivo either to deplete or functionally block T cells to create a tolerance permissive environment. Short courses of **non-depleting CD4** and CD8 **antibodies** were used to induce tolerance separately in **CD4**+ and CD8+ T cells either to foreign **immunoglobulins**, bone marrow, or skin grafts. Tolerance was obtained to minor (non-MHC) transplantation antigens without T cell depletion even in actively sensitized mice, or to MHC plus minor antigens presented directly by skin grafts using combinations of depleting followed by blockading **CD4** and CD8 **antibodies** . In all cases, tolerance was specific to the antigen/tissue given under cover of **antibody** treatment, and in one example it could be shown that T cells directed to MLS-1a had been forced into an anergic state. This induction of tolerant, anergic T cells in the periphery is able to explain many of the features associated with tolerance, not only in the model systems using foreign antigens, but also in the normal regulation of anti-self responses and its failure in autoimmune diseases. It is our new found ability to use antigen under the cover of **antibody** treatment to accurately control the pattern of tolerant T cells in vivo that we refer to by using the term 'reprogramming'. We also describe the clinical treatment of one patient with an autoimmune vasculitis based on the ideas developed from the mouse models. (47 Refs.)

17/7/6 (Item 1 from file: 351)
DIALOG(R)File 351:DERWENT WPI

008503137
WPI Acc No: 91-007221/**199101**
Non-depleting CD4 and CD8 monoclonal **antibodies** - for inducting tolerance to foreign antigens in transplant rejection, auto-immune disease, etc
Patent Assignee: COBBOLD S P (COBB-I); WALDMANN H (WALD-I); WELLCOME FOUND LTD (WELL); GLAXO WELLCOME INC (GLAX)
Inventor: COBBOLD S P; WALDMANN H
Number of Countries: 025 Number of Patents: 015
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
WO 9015152	A	19901213					199101 B

PT 94214	A	19910208					199109
AU 9057258	A	19910107					199115
EP 474691	A	19920318	EP 90908270	A	19900531		199212
ZA 9004174	A	19920226	ZA 904174	A	19900530		199213
DD 296843	A5	19911219	DD 341218	A	19900531	A61K-039/395	199221
JP 4505919	W	19921015	JP 90508030	A	19900531	A61K-039/395	199248
			WO 90GB840	A	19900531		
HU 61341	T	19921230	HU 905134	A	19900531	C12P-021/08	199306
			WO 90GB840	A	19900531		
AU 657255	B	19950309	AU 9057258	A	19900531	C12P-021/08	199520
EP 474691	B1	19961113	EP 90908270	A	19900531	C12P-021/08	199650
			WO 90GB840	A	19900531		
DE 69029134	E	19961219	DE 629134	A	19900531	C12P-021/08	199705
			EP 90908270	A	19900531		
			WO 90GB840	A	19900531		
ES 2096588	T3	19970316	EP 90908270	A	19900531	C12P-021/08	199718
NZ 233889	A	19970624	NZ 233889	A	19900531	A61K-039/395	199732
BR 1100287	A3	19970916	BR 971100287	A	19970415	C12P-021/08	199744
US 5690933	A	19971125	US 91768868	A	19910727	A61K-039/395	199802
			US 9347344	A	19930329		
			US 94181170	A	19940113		
			US 94289532	A	19940812		

Priority Applications (No Type Date): GB 8912497 A 19890531
Cited Patents: 4.Jnl.Ref
Patent Details:

Patent	Kind	Lan	Pg	Filing Notes	Application	Patent
WO 9015152	A					
Designated States (National): AU CA FI HU JP KR US						
Designated States (Regional): AT BE CH DE DK ES FR GB IT LU NL SE						
EP 474691	A		44			
Designated States (Regional): AT BE CH DE DK ES FR GB IT LI LU NL SE						
ZA 9004174	A		57			
JP 4505919	W		19	Based on		WO 9015152
HU 61341	T			Based on		WO 9015152
AU 657255	B			Previous Publ.		AU 9057258
				Based on		WO 9015152
EP 474691	B1	E	32	Based on		WO 9015152
Designated States (Regional): AT BE CH DE DK ES FR GB IT LI LU NL SE						
DE 69029134	E			Based on		EP 474691
				Based on		WO 9015152
ES 2096588	T3			Based on		EP 474691
US 5690933	A		23	Cont of	US 91768868	
				Cont of	US 9347344	
				Cont of	US 94181170	

Abstract (Basic): WO 9015152 A

Non depleting CD4 and CD8 monoclonal **antibodies** are claimed for use in inducing tolerance to an antigen. The use of these **antibodies** and packs contg. them are also claimed. The prods. may also contain a depleting **CD4** monoclonal **antibody** and/or a depleting CD8 monoclonal **antibody**.

Single dose for a human is 1-400mg (esp. 3-30mg) of **antibody** . Admin. is parenteral e.g. intravenous.

USE/ADVANTAGE - For producing tolerance to foreign **immunoglobulins**, bone marrow and skin grafts. To treat autoimmune diseases without the need for long term chemotherapy and to produce tolerance to therapeutic polypeptides such as interferon, IL-II or TNF. (44pp Dwg.No.0/13)

Abstract (Equivalent): EP 474691 B

Use of a **non-depleting** anti-**CD4** monoaconal **antibody**, ie an **antibody** which causes depletion of fewer than 50% of **CD4**+ T-cells from the periphery as measured by changes in the peripheral blood lymphocyte numbers, for the manufacture

of a medicament for the induction of a state of immunological tolerance to an antigen by a method which comprises administering said **non-depleting** anti-**CD4** monoclonal **antibody** to a subject together with a **non-depleting** anti-CD8 monoclonal **antibody**, ie an **antibody** which causes depletion of fewer than 50% of CD8+ T-cells from the periphery as measured by changes in the peripheral blood lymphocyte numbers, to induce an immunological tolerance permissive environment within said subject by means of said **antibodies** in the presence of said antigen.

(Dwg.0/11b

Abstract (Equivalent): US 5690933 A

Non depleting CD4 and CD8 monoclonal **antibodies** are claimed for use in inducing tolerance to an antigen. The use of these **antibodies** and packs contg. them are also claimed. The prods. may also contain a depleting **CD4** monoclonal **antibody** and/or a depleting CD8 monoclonal **antibody**.

Single dose for a human is 1-400mg (esp. 3-30mg) of **antibody** . Admin. is parenteral e.g. intravenous.

USE/ADVANTAGE - For producing tolerance to foreign **immunoglobulins**, bone marrow and skin grafts. To treat autoimmune diseases without the need for long term chemotherapy and to produce tolerance to therapeutic polypeptides such as interferon, IL-II or TNF.

Dwg.0/13b

Derwent Class: B04; D16

International Patent Class (Main): A61K-039/395; C12P-021/08

International Patent Class (Additional): A61K-037/02; A61K-039/39; C07K-015/28; C07K-016/24; C07K-016/42; C12N-015/00; G01N-000/00

? t s13/7/2

13/7/2 (Item 2 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

7104252 BIOSIS Number: 88026997

AN INCREASE IN THE SURVIVAL OF MURINE H-2-MISMATCHED CULTURED FETAL PANCREAS ALLOGRAFTS USING DEPLETING OR **NONDEPLETING** ANTI-**CD4** MONOCLONAL **ANTIBODIES** AND A FURTHER INCREASE WITH THE ADDITION OF CYCLOSPORINE

BURKHARDT K; CHARLTON B; MANDEL T E

TRANSPANTATION UNIT, WALTER AND ELIZA HALL INST. MED. RES., POST OFFICE, ROYAL MELBOURNE HOSP., VICTORIA 3050, AUST.

TRANSPLANTATION (BALTIMORE) 47 (5). 1989. 771-775. CODEN: TRPLA

Full Journal Title: TRANSPLANTATION (Baltimore)

Language: ENGLISH

Depletion of **CD4**+ T lymphocytes with monoclonal **antibodies** (mAbs) has been shown to prolong allograft survival in mice. In this study, two rat anti-**CD4** mAbs, H129.19 and GK1.5, were administered either alone or in combination with cyclosporine (CsA) to recipients of MHC-mismatched (H-2k to H-2d) cultured fetal pancreas allografts to determine their effect on graft survival. When compared with control mice, splenic **CD4**+ cells of GK1.5-treated mice were depleted by > 95%, but in H129.19-treated mice no depletion of **CD4** + cells occurred. Instead, rat Ig was present on the surface of **CD4** + cells in H129.19-treated mice. Anti-**CD4** therapy with either H129.19 or GK1.5 prolonged fetal pancreas allograft survival to a similar extent, but did not lead to indefinitive survival. Blockade of the **CD4** antigen by the mAb H129.19 was as effective as the depletion of **CD4**+ cells by GK1.5 in prolonging allograft survival. Rejection of grafts by day 28 posttransplantation occurred in the absence of **CD4** + cells, as determined by both flow cytometric examination of spleen cells and immunoperoxidase staining of the graft site. CsA alone did not prolong graft survival, but its addition to either H129.19 or GK1.5 mAb treatment significantly increased the survival rate of grafts at 28 days compared

with mAb treatment alone. These results suggest that **CD4**+ cell depletion is not essential for effective anti-**CD4** mAb therapy-and, further, that CsA may have a direct inhibitory effect on CD8+ cells during allograft rejection.